Liquid dosage form pharmaceutical composition comprising plasmid DNA

By using expression vectors and specific formula buffers in liquid dosage forms, the stability and safety of DNA constructs are solved, and efficient development of plasmid DNA liquid dosage forms is achieved, ensuring the long-term stability and safety of the drug.

CN118922176APending Publication Date: 2024-11-08HELIXMITH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280094119.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-24
Filing Date
2022-12-01
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The physical and chemical stability of existing DNA or RNA constructs is affected by preparations and dosage forms. The development of liquid dosage forms can improve the safety and product competitiveness of drugs, but there is a risk of inhomogeneity and pollution during the reconstruction process.

Method used

A liquid dosage form containing plasmid DNA was developed, using expression vectors and selection marker genes, combining buffers and salts to ensure the stability and safety of plasmid DNA through ingredients such as potassium phosphate, sodium chloride and mannitol. Maintain pH and stability.

Benefits of technology

The long-term stability of plasmid DNA is achieved, ensuring that the high super spiral morphology remains after storage under different temperature conditions, improving the safety and stability of the drug, and reducing the risks during the reconstruction process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922176A_ABST
    Figure CN118922176A_ABST
Patent Text Reader

Abstract

The present invention relates to a liquid dosage form pharmaceutical composition comprising plasmid DNA. The liquid dosage form containing plasmid DNA of the present invention shows an excellent effect in the storage stability of plasmid DNA as a pharmaceutical active ingredient, and can be effectively used as a pharmaceutical composition having excellent product stability and safety.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the priority of Korean Patent Application No. 10-2022-0036970 filed in the Korean Patent Office on March 24, 2022, the entire contents of which are hereby incorporated by reference into this application.

[0002] The present invention relates to a liquid dosage pharmaceutical composition comprising plasmid DNA. [Background technology]

[0003] Gene therapy with direct in vivo delivery of nucleic acid constructs that are not packaged by viruses or virus-like particles (so-called "naked" DNA or RNA constructs) has been shown to be effective in the treatment of a variety of diseases, and this has been substantially clinically demonstrated. For example, direct intramuscular injection of DNA plasmid constructs expressing two isoforms of human HGF protein (i.e., pCK-HGF-X7, also known as "VM202") has been shown to be effective in the treatment of neuropathic pain. In a phase II clinical trial, VM202 was injected into the calf muscle of patients with diabetic peripheral neuropathy, which showed a significant reduction in pain. If the treatment was given for 2 days at 2-week intervals, the symptom relief provided was sufficient to improve the patient's quality of life for 3 months (Kessler et al., Annals Clin. Transl. Neurology 2(5): 465-478(2015)). The same DNA plasmid construct also showed an effect in the treatment of patients with amyotrophic lateral sclerosis (ALS). In a Phase I clinical trial, nearly half of ALS patients maintained a stable or improved state after administration of VM202. At 1 month, 2 months, and 3 months, 47%, 50%, and 24% of the subjects, respectively, showed no reduction or improvement in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale-revised) scores, which represents the physical function of ALS patients. This is lower than what was observed in the control group in the past (Robert L. Sufit et al., Amyotrophic Lateral Sclerosis and Frontoemporal Degeneration 18:269-278 (2017)).

[0004] However, it is known that the physical and chemical stability of DNA or RNA constructs is affected by the final formulation and dosage form, storage conditions, etc. Usually, drug dosage forms are provided in freeze-dried dosage forms for storage stability, and in order to administer to patients, they must be reconstituted with water for injection. When reconstructing such drugs, if the correct guidelines are not followed, the drugs cannot be reconstituted uniformly, and there is a risk of drug loss or contamination during administration. Therefore, when drugs are provided in liquid dosage forms that are not freeze-dried, safety and product competitiveness can be improved. Therefore, it is necessary to develop liquid dosage forms of naked DNA-based drugs with excellent stability and safety. [Summary of the invention]

[0005]

Technical issues

[0006] The present invention provides a liquid dosage form comprising plasmid DNA.

[0007]

Technical solution

[0008] According to one embodiment of the present invention, the present invention provides a liquid dosage form comprising plasmid DNA.

[0009] The term "liquid formulation" in the present specification refers to a pharmaceutical composition in liquid form as described in the present application, comprising plasmid DNA and at least one pharmaceutically acceptable carrier or excipient.

[0010] The liquid dosage form of the present invention relates to a general liquid dosage form of plasmid DNA that can be used regardless of the type of plasmid DNA, and the purpose of the liquid dosage form of the present invention is not limited to a liquid dosage form for plasmid DNA (eg, VM202) used as an example of the present invention.

[0011] In one embodiment of the present invention, the plasmid DNA encodes human HGF or a variant thereof.

[0012] In one example of the present invention, the plasmid DNA may be VM202, but is not limited thereto.

[0013] In one example of the present invention, the plasmid DNA further comprises a promoter. The promoter is operably linked to the protein-encoding nucleic acid molecule in the plasmid DNA. In this specification, the term "operably linked" refers to the functional combination between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence, or an array of transcriptional regulatory factor binding epitopes) and other nucleic acid sequences, and the regulatory sequence regulates the transcription and / or interpretation of the other nucleic acid sequences in this way.

[0014] For example, the vector of the present invention is an expression vector. When a eukaryotic cell is used as a host, a promoter derived from the genome of a mammalian cell (e.g., a metallothionein promoter, a β (beta) actin promoter, a human hemoglobin promoter, and a human creatine promoter) or a promoter derived from a mammalian virus (e.g., an adenovirus late promoter, a Bosnia virus 7.5K promoter, an SV40 promoter, a cytomegalovirus promoter, a tk promoter of HSV, a mouse mammary tumor virus (MMTV) promoter, an LTR promoter of HIV, a promoter of moloney virus, a promoter of Epstein-Barr virus (EBV), and a promoter of Rous sarcoma virus (RSV)) can be used, and usually has a polyadenylation sequence as a transcription termination sequence.

[0015] On the other hand, the expression vector of the present invention may contain a selectable marker gene and / or a reporter gene as a selectable marker for evaluating the transformation of the expression vector and protein expression.

[0016] Selectable marker genes include antibiotic resistance genes commonly used in the technical field of the present invention, for example, genes with resistance to ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline, etc. Reporter genes include luciferase, β-galactosidase, chloramphenicol acetyltransferase and green fluorescent protein, etc., but are not limited thereto.

[0017] The method of introducing the recombinant vector of the present invention into cells and expressing it is well known in the technical field to which the present invention belongs. The vector can be easily introduced into the host cell by the known methods in the technical field to which the present invention belongs, for example, mammalian, bacterial, yeast or insect cells. For example, the vector can be delivered to the host cell by physical, chemical or biological means. The above-mentioned physical means include calcium phosphate precipitation, lipid transfection, particle bombardment, microinjection, electroporation, etc. The above-mentioned chemical means include colloidal dispersion systems, including, for example, super macromolecular complexes, nanocapsules, droplets, magnetic beads and water-in-oil emulsions, micelles, mixed micelles, and lipid-based systems containing liposomes. In addition, the above-mentioned biological means include the use of DNA or RNA vectors such as the above-mentioned lentivirus and retrovirus. But it is not limited to this.

[0018] The term "VM202" in this specification refers to a plasmid DNA comprising HGF-X7 (SEQ ID NO: 13) cloned in a pCK vector (SEQ ID NO: 6) and a pCK vector, also referred to as pCK-HGF-X7. VM202 was deposited in the Korean Collection of Microorganisms (KCCM) on March 12, 2002 under the Budapest Treaty with the deposit number KCCM-10361.

[0019] As used in the present application, the term "isoforms of HGF" refers to polypeptides having an amino acid sequence that is at least 80% identical to the amino acid sequence of a naturally occurring HGF polypeptide in an animal. The above term includes polypeptides having an amino acid sequence that is at least 80% identical to any full-length wild-type HGF polypeptide, including polypeptides having an amino acid sequence that is at least 80% identical to a naturally occurring HGF allele variant, splice variant, or deletion variant. In the present invention, the isoforms of HGF include two or more isoforms selected from the group consisting of full-length HGF (flHGF), deleted variant HGF (dHGF), NK1, NK2, and NK4. According to a more specific example of the present invention, the isoforms of HGF used in the method described in the present application include flHGF (sequence 1) and dHGF (sequence 2).

[0020] The terms "human flHGF", "flHGF" and "fHGF" are used to refer to a protein consisting of amino acids 1-728 of human HGF protein and are used interchangeably in this application. The amino acid sequence of flHGF is provided in SEQ ID NO: 1.

[0021] The terms "human dHGF" and "dHGF" are used to refer to variants of HGF proteins produced by alternative splicing of the human HGF gene, and can be used interchangeably in this application. Specifically, "human dHGF" or "dHGF" refers to a human HGF protein in which 5 amino acids (F, L, P, S and S) are missing from the first kringle domain of the α chain of the full-length HGF sequence. Human dHGF is 723 amino acids in length. The amino acid sequence of human dHGF is provided in SEQ ID NO: 2.

[0022] In one embodiment of the present invention, the plasmid DNA encodes SDF-1, IGF-1, c-Met, or fragments / isomers / variants thereof.

[0023] The term SDF-1 (stromal cell-derived factor 1) of the present invention is also called CXC motif chemokine 12 (CXCL12), which is a chemokine protein encoded by the CXCL12 gene. SDF-1 is expressed in many cell nuclear tissues and is divided into SDF-1α (alpha) and SDF-1β (beta). SDF-1 is known to play an important role in angiogenesis, wound healing, neural development, etc.

[0024] An exemplary amino acid sequence of human SDF-1α is provided in SEQ ID NO:21.

[0025] An exemplary nucleotide sequence encoding the above-mentioned human SDF-1α is provided in SEQ ID NO:17.

[0026] The term IGF-1 (insulin-like growth factor 1) of the present invention is also called somatomedin C, which is a hormone with a similar structure to insulin. IGF-1 plays an important role by being associated with the promotion of cell proliferation during the growth phase of childhood. IGF-1 is encoded by the IGF1 gene, stimulates the growth of various types of cells and inhibits apoptosis, and is known to increase protein production in cells.

[0027] An exemplary amino acid sequence of the Ea isomer of human IGF-1 is provided in SEQ ID NO: 19. An exemplary amino acid sequence of the Ec isomer of human IGF-1 is provided in SEQ ID NO: 20.

[0028] The term c-Met protein of the present invention is also referred to as tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR). C-Met is encoded by the MET gene and is a kinase receptor required for embryonic development, tissue formation, cell division and wound healing with tyrosine kinase activity. In one example of the present invention, the plasmid DNA may be pCK-SDF-1a (WO2016 / 048105A1), pTx-IGF-1X10 (WO2020 / 016655A2), pCMV3-cMet-flag (Sino Biological Inc., China), or a combination thereof, but is not limited thereto.

[0029] In one embodiment of the present invention, the pTx is a plasmid vector derived from pCK. pTx is generated by two consecutive mutagenesis of pCK. It is generated by deleting unnecessary sequences between the kanamycin resistance gene and ColE1 of pCK and optimizing the length of the HCMV intron sequence.

[0030] In one embodiment of the present invention, the pCMV3 is a vector for expressing mammalian proteins induced by the CMV promoter.

[0031] In one example of the present invention, the liquid dosage form contains plasmid DNA as the active ingredient of the pharmaceutical composition. The plasmid DNA may contain genetic material for gene therapy. Specifically, the plasmid DNA may correct the function of a defective gene or transcript, or encode a polypeptide, a sense oligonucleotide, an antisense oligonucleotide or RNA (coding or non-coding; for example, siRNA (small interfering RNA), shRNA (short hairpin RNA), microRNA and their antisense counterparts (e.g., antagoMi R)). The dosage form containing any plasmid DNA known in the technical field to which the present invention belongs used in gene therapy is included within the scope of the present invention.

[0032] In one example of the present invention, the liquid dosage form comprises a plasmid DNA at a concentration of 0.01-5 mg / ml. More specifically, it may comprise a concentration of 0.01 mg / ml to 5 mg / ml, 0.01 mg / ml to 3 mg / ml, 0.01 mg / ml to 2 mg / ml, 0.01 mg / ml to 1 mg / ml, 0.01 mg / ml to 0.75 mg / ml, 0.01 mg / ml to 0.6 mg / ml, 0.01 mg / ml to 0.5 mg / ml, 0.1 mg / ml to 5 mg / ml, 0.1 mg / ml to 3 mg / ml, 0.1 mg / ml to 2 mg / ml, 0.1 mg / ml to 1 mg / ml, 0.1 mg / ml to 0.75 mg / ml, 0.1 mg / ml to 0.6 mg / ml, 0.1 mg / ml to 0.5 mg / ml, Plasmid DNA at a concentration of 0.2 mg / ml to 5 mg / ml, 0.2 mg / ml to 3 mg / ml, 0.2 mg / ml to 2 mg / ml, 0.2 mg / ml to 1 mg / ml, 0.2 mg / ml to 0.75 mg / ml, 0.2 mg / ml to 0.6 mg / ml, 0.2 mg / ml to 0.5 mg / ml, 0.3 mg / ml to 5 mg / ml, 0.3 mg / ml to 3 mg / ml, 0.3 mg / ml to 2 mg / ml, 0.3 mg / ml to 1 mg / ml, 0.3 mg / ml to 0.75 mg / ml, 0.3 mg / ml to 0.6 mg / ml, 0.3 mg / ml to 0.5 mg / ml, or 0.5 mg / ml.

[0033] The plasmid DNA may be 2000 base pairs to 15000 base pairs, 2000 base pairs to 10000 base pairs, 2000 base pairs to 9000 base pairs, 2000 base pairs to 8000 base pairs, 2000 base pairs to 7000 base pairs, 2000 base pairs to 6000 base pairs, 2000 base pairs to 5000 base pairs, 3000 base pairs to 15000 base pairs, 3000 base pairs to 10000 base pairs, 3000 base pairs to 15000 base pairs, 3000 base pairs to 10000 base pairs, 3000 base pairs to 20000 base pairs, 3000 base pairs to 20000 base pairs, 3000 base pairs to 20000 base pairs, 3000 base pairs to 3 ... The plasmid DNA may be a polynucleotide of a length within the range provided in the present application.

[0034] The above-mentioned liquid dosage form of the present invention is used to improve the stability of plasmid DNA. The stability of the above-mentioned plasmid DNA can be determined based on methods known in the technical field to which the present invention belongs. In particular, the stability can be determined based on the three-dimensional structure (conformation) of the plasmid DNA, for example, based on the presence of a more stable supercoiled form or a less stable open circle and linear form. The three-dimensional structure (conformation) of the plasmid DNA can be determined by capillary electrophoresis or HPLC (High-Pressure Liquid Chromatography) of a sample containing plasmid DNA. The supercoiled DNA content can be measured under various conditions by comparison with the open circle and linear forms.

[0035] In one example of the present invention, at least 90% of the plasmid DNA is supercoiled. In some examples, at least 92.5% of the plasmid DNA in the liquid composition is supercoiled, but not limited thereto. In some examples, at least 95% of the plasmid DNA in the liquid composition is supercoiled. In some examples, at least 97% of the plasmid DNA in the liquid composition is supercoiled. In some examples, at least 98% of the plasmid DNA in the liquid composition is supercoiled.

[0036] In one example of the present invention, the liquid composition further comprises a buffer to maintain the pH of the pharmaceutical composition. The buffer may comprise a buffer compound known in the art to which the present invention belongs, for example, TAPS, N,N-bicine, Tris, N-[tris(hydroxymethyl)methyl]glycine, TAPSO, HEPES, TES, MPOS, PIPES, Cacodylate or MES. The buffer may comprise citric acid, monopotassium phosphate, boric acid or diethyl barbituric acid. The buffer may be PBS, HEPES, TRIS or TRIS / EDTA buffer. The buffer may be other phosphate buffers. Phosphate buffers may comprise a mixture of monobasic dihydrogen phosphate and dibasic monohydrogen phosphate.

[0037] The buffer may be a potassium phosphate buffer. The potassium phosphate buffer may contain potassium phosphate at a concentration of about 30-50 mM, about 35-50 mM, about 40-50 mM, about 45-50 mM, about 30-45 mM, about 35-45 mM, about 40-45 mM, about 30-40 mM, about 35-40 mM or about 40 mM.

[0038] The pH of the buffer contained in the liquid composition may be about 7 to 9. In some examples, the pH may be about 7 to 9, about 7.5 to 9, about 8 to 9, about 7 to 8.5, about 7.5 to 8.5, about 8 to 8.5, about 7 to 8, about 7.5 to 8, or about 8.

[0039] In one embodiment of the present invention, the liquid dosage form comprises about 30-50 mM potassium phosphate and has a pH of about 7.5-8.5.

[0040] In one embodiment of the present invention, the liquid dosage form further comprises salt. The salt may be sodium chloride (NaCl). The concentration of the sodium chloride may be about 0.5-1.5%, about 0.5-1.4%, about 0.5-1.3%, about 0.5-1.2%, about 0.5-1.1%, about 0.5-1.0%, about 0.5-0.9%, about 0.6-1.5%, about 0.6-1.4%, about 0.6-1.3%, about 0.6-1.2%, about 0.6-1.1%, about 0.6-1.0%, about 0.6-0. 9%, about 0.7-1.5%, about 0.7-1.4%, about 0.7-1.3%, about 0.7-1.2%, about 0.7-1.1%, about 0.7-1.0%, about 0.7-0.9%, about 0.8-1.5%, about 0.8-1.4%, about 0.8-1.3%, about 0.8-1.2%, about 0.8-1.1%, about 0.8-1.0%, about 0.8-0.9% or 0.9%.

[0041] In one embodiment of the present invention, the liquid dosage form comprises about 40 mM potassium phosphate.

[0042] In one embodiment of the present invention, the liquid dosage form comprises about 0.9% sodium chloride.

[0043] In one embodiment of the present invention, the pH of the liquid dosage form is about 8.0.

[0044] In one example of the present invention, the liquid dosage form may contain about 40 mM potassium phosphate, about 0.9% sodium chloride, and the pH may be about 8.0.

[0045] In one embodiment of the present invention, the plasmid in the above liquid dosage form still maintains a supercoiled percentage (SC%, supercoiled%) of 80-100, 85-100 SC%, 90-100 SC% or 95-100 SC% after being stored at a temperature of 2-8°C for 3 months, 4 months, 5 months or 6 months.

[0046] In one embodiment of the present invention, the plasmid in the liquid dosage form still maintains 80-100 SC%, 81-100 SC%, 82-100 SC%, 83-100 SC%, 84-100 SC% after being stored at a temperature of 15-30°C for at least 3 months, 4 months, 5 months or 6 months. The storage temperature is 15-30°C, 16-30°C, 17-30°C, 18-30°C, 19-30°C, 20-30°C, 21-30°C, 22-30°C, 23-30°C, 24-30°C, 25-30°C, 15-28°C, 16-28°C, 17-28°C, 18-28°C, 19-28°C, 20-28°C, 21-28°C, 22-28°C, 23-28°C, 24-28°C, 25-28°C, 15 -27°C, 16-27°C, 17-27°C, 18-27°C, 19-27°C, 20-27°C, 21-27°C, 22-27°C, 23-27°C, 24-27°C, 25-27°C, 15-26°C, 16-26°C, 17-26°C, 18-26°C, 19-26°C, 20-26°C, 21-26°C, 22-26°C, 23-26°C, 24-26°C, 25-26°C or 25°C, but is not limited thereto. The above-mentioned liquid dosage form of the present invention contains an aqueous solution containing a stabilizing amount of sugar in order to improve the stability of the plasmid DNA. The above-mentioned sugar can be sucrose, trehalose, mannitol or sorbitol.

[0047] Therefore, the liquid dosage form of the present invention may further comprise sucrose, trehalose, mannitol, sorbitol, leucine or a combination thereof.

[0048] In one embodiment of the present invention, the liquid dosage form further comprises about 1-2% sucrose, about 0.5-2% trehalose, about 0.01-1% sorbitol, about 0.05-0.5% leucine, or a combination thereof. In one embodiment of the present invention, the liquid dosage form comprises about 1.5% sucrose, about 0.5-1.5% trehalose, about 0.05-0.25% sorbitol, about 0.1-0.5% leucine, or a combination thereof.

[0049] In a liquid dosage form of plasmid DNA according to yet another embodiment of the present invention, the liquid dosage form of the present invention may further comprise about 0.15 to 1.5% of mannitol in the liquid dosage form of the above embodiment.

[0050] In one embodiment of the present invention, the liquid dosage form comprises about 0.15% to 1.5%, about 0.15% to 1.25%, about 0.15% to 1.0%, about 0.15% to 0.75, about 0.15% to 0.5%, about 0.15% to 0.25%, about 0.25% to 1.5%, about 0.25% to 1.25%, about 0.25% to 1.0%, about 0.25% to 0.75, about Mannitol can be present in a concentration of about 0.25% to 0.5%, about 0.3% to 1.25%, about 0.3% to 1.0%, about 0.3% to 0.75%, about 0.3% to 0.5%, about 0.5% to 1.25%, about 0.5% to 1.0%, about 0.5% to 0.75%, about 1.5%, about 1.25%, about 1.0%, about 0.75%, about 0.5% or about 0.25%, but is not limited thereto.

[0051] In this specification, the liquid dosage form according to one embodiment of the present invention is named as B dosage form.

[0052] In one embodiment of the present invention, the plasmid DNA in the liquid dosage form still maintains 90-100 SC% after being stored at 2-8°C for at least 3 months, 4 months, 5 months or 6 months.

[0053] In one embodiment of the present invention, the plasmid DNA in the liquid dosage form still maintains 60-100, 70-100, 75-100, 76-100, 77-100, 78-100, 79-100 or 80-100 SC% after being stored at a temperature of 15-30°C for at least 3 months, 4 months, 5 months or 6 months. The above storage temperatures are 15-30°C, 16-30°C, 17-30°C, 18-30°C, 19-30°C, 20-30°C, 21-30°C, 22-30°C, 23-30°C, 24-30°C, 25-30°C, 15-28°C, 16-28°C, 17-28°C, 18-28°C, 19-28°C, 20-28°C, 21-28°C, 22-28°C, 23-28°C, 24-28°C, 25-28°C, 15-27°C, 16-27°C, 17-27°C, 18-27°C, 19-27°C, 20 -27°C, 21-27°C, 22-27°C, 23-27°C, 24-27°C, 25-27°C, 15-26°C, 16-26°C, 17-26°C, 18-26°C, 19-26°C, 20-26°C, 21-26°C, 22-26°C, 23-26°C, 24-26°C, 25-26°C, 15-25°C, 16-25°C, 17-25°C, 18-25°C, 19-25°C, 20-25°C, 21-25°C, 22-25°C, 23-25°C, 24-25°C or 25°C, but is not limited to this.

[0054] In the liquid dosage form of plasmid DNA according to another embodiment of the present invention, the liquid dosage form of the present invention comprises about 0.001 to 0.3% mannitol, about 0.05 to 0.5% sorbitol, about 0.05 to 0.5% sucrose, about 0.15 to 3% trehalose, about 0.01 to 1% leucine, or a combination thereof in the liquid dosage form of the above embodiment.

[0055] In this specification, the liquid dosage form according to one embodiment of the present invention is named as C dosage form.

[0056] In one example of the present invention, the liquid dosage form may contain about 0.001% to 0.3%, about 0.005% to 0.3%, about 0.01% to 0.3%, about 0.02% to 0.3%, about 0.03% to 0.3%, about 0.04% to 0.3%, about 0.05% to 0.3%, about 0.001% to 0.25%, about 0.005% to 0.25%, about 0.01% to 0.25%, about 0.02% to 0.25%, about 0.03% to 0.25%, about 0.04% to 0.25%, about 0.05% to 0.25%, about 0.001% to 0.25%, about 0.005% to 0.25%, about 0.01% to 0.25%, about 0.02% to 0.25%, about 0.03% to 0.25%, about 0.04% to 0.25%, about 0.05% to 0.25%, about 0.001% to 0.25%, about 0.005% to 0.25%. .2%, about 0.01% to 0.2%, about 0.02% to 0.2%, about 0.03% to 0.2%, about 0.04% to 0.2%, about 0.05% to 0.2%, about 0.001% to 0.15%, about 0.005% to 0.15%, about 0.01% to 0.15%, about 0.02% to 0.15%, about 0.03% to 0.15%, about 0.04% to 0.15%, about 0.05% to 0.15%, about 0.001% to 0.1%, about 0.005% to 0.1%, about 0.01% to 0.1%, about 0.02% to 0.1%, about 0.03% to 0.15%, about 0.04% to 0.15%, about 0.05% to 0.15%, about 0.001% to 0.1%, about 0.005% to 0.1%, about 0.01% to 0.1%, about 0.02% to 0.1%, about 0.03% to 0.1%, about 0 .04% to 0.1%, about 0.05% to 0.1%, about 0.001% to 0.075%, about 0.005% to 0.075%, about 0.01% to 0.075%, about 0.02% to 0.075%, about 0.03% to 0.075%, about 0.04% to 0.075%, about 0.05% to 0.075%, about 0.001% to 0.07%, about 0.005% to 0.07%, about 0.01% to 0.07%, about 0.02% to 0.07%, about 0.03% to 0.07%, about 0.04% to 0.07%, about 0.05% to 0.075%, about 0.001% to 0.07%, about 0.005% to 0.07%, about 0.01% to 0.07%, about 0.02% to 0.07%, about 0.03% to 0.07%, about 0.04% to 0.07%, about 0.05% to 0.07%, about 0.001 % to 0.06%, about 0.005% to 0.06%, about 0.01% to 0.06%, about 0.02% to 0.06%, about 0.03% to 0.06%, about 0.04% to 0.06%, about 0.05% to 0.06%, about 0.001% to 0.05%, about 0.005% to 0.05%, about 0.01% to 0.05%, about 0.02% to 0.05%, about 0.03% to 0.05%, about 0.04% to 0.05%, about 0.01%, about 0.03%, about 0.05%, about 0.07%, about 0.075% or about 0.1% concentration of mannitol, but is not limited thereto.

[0057] In one example of the present invention, the liquid dosage form comprises sorbitol in a concentration of about 0.05% to 0.5%, about 0.075% to 0.5%, about 0.1% to 0.5%, about 0.125% to 0.5%, about 0.15% to 0.5%, about 0.2% to 0.5%, about 0.25% to 0.5%, about 0.3% to 0.5%, about 0.35% to 0.5%, about 0.4% to 0.5%, about 0.05%, 0.075%, about 0.1% or about 0.15%, but is not limited thereto.

[0058] In one example of the present invention, the liquid dosage form comprises sucrose at a concentration of about 0.05% to 0.5%, about 0.075% to 0.5%, about 0.1% to 0.5%, about 0.125% to 0.5%, about 0.15% to 0.5%, about 0.2% to 0.5%, about 0.25% to 0.5%, about 0.3% to 0.5%, about 0.35% to 0.5%, about 0.4% to 0.5%, about 0.05%, 0.075%, about 0.1%, 0.15%, about 0.2% or about 0.3%, but is not limited thereto.

[0059] In one embodiment of the present invention, the liquid dosage form comprises about 0.15% to 3%, about 0.15% to 2.5%, about 0.15% to 2%, about 0.15% to 1.75%, about 0.15% to 1.5%, about 0.15% to 1.25%, about 0.15% to 1%, about 0.15% to 0.8%, about 0.15% to 0.75%, about 0.15% to 0.7%, about 0.15% to 0.6%, about 0.15% to 0.5%, about 0.25% to 3%, about 0.25% to 2 .5%, about 0.25% to 2%, about 0.25% to 1.75%, about 0.25% to 1.5%, about 0.25% to 1.25%, about 0.25% to 1%, about 0.25% to 0.8%, about 0.25% to 0.75%, about 0.25% to 0.7%, about 0.25% to 0.6%, about 0.25% to 0.5%, about 0.5% to 3%, about 0.5% to 2.5%, about 0.5% to 2%, about 0.5% to 1.75%, about 0.5% to 1.5%, about 0. 5% to 1.25%, about 0.5% to 1%, about 0.5% to 0.8%, about 0.5% to 0.75%, about 0.5% to 0.7%, about 0.5% to 0.6%, about 0.75% to 3%, about 0.75% to 2.5%, about 0.75% to 2%, about 0.75% to 1.75%, about 0.75% to 1.5%, about 0.75% to 1.25%, about 0.75% to 1%, about 0.75% to 0.8%, about 1% to 3%, about 1% to 2.5%, about 1% to 2%, Trehalose at a concentration of about 1% to 1.75%, about 1% to 1.5%, about 1% to 1.25%, about 1.25% to 3%, about 1.25% to 2.5%, about 1.25% to 2%, about 1.25% to 1.75%, about 1.25% to 1.5%, about 1.5% to 3%, about 1.5% to 2.5%, about 1.5% to 2%, about 1.5% to 1.75%, 0.5%, about 1.0%, about 1.25%, about 1.5%, about 2%, about 2.5% or about 3%, but is not limited thereto.

[0060] In one embodiment of the present invention, the liquid dosage form comprises about 0.01% to 1%, about 0.01% to 0.9%, about 0.01% to 0.8%, about 0.01% to 0.7%, about 0.01% to 0.6%, about 0.01% to 0.5%, about 0.01% to 0.4%, about 0.01% to 0.3%, about 0.01% to 0.2%, about 0.01% to 0.1%, about 0.03% to 1%, about 0.03% to 0.9%, about 0.03% to 0.8%, about 0.03% to 0.7%, about 0.03% to 0.6%, about 0.03% to 0. .5%, about 0.03% to 0.4%, about 0.03% to 0.3%, about 0.03% to 0.2%, about 0.03% to 0.1%, about 0.05% to 1%, about 0.05% to 0.9%, about 0.05% to 0.8%, about 0.05% to 0.7%, about 0.05% to 0.6%, about 0.05% to 0.5%, about 0.05% to 0.4%, about 0.05% to 0.3%, about 0.05% to 0.2%, about 0.05% to 0.1%, about 0.075% to 1%, about 0.075% to 0.9%, about 0.075% to 0. .8%, about 0.075% to 0.7%, about 0.075% to 0.6%, about 0.075% to 0.5%, about 0.075% to 0.4%, about 0.075% to 0.3%, about 0.075% to 0.2%, about 0.075% to 0.1%, about 0.08% to 1%, about 0.08% to 0.9%, about 0.08% to 0.8%, about 0.08% to 0.7%, about 0.08% to 0.6%, about 0.08% to 0.5%, about 0.08% to 0.4%, about 0.08% to 0.3%, about 0.08% to 0.2%, about 0.08% to 0.1%, about 0.09% to 1%, about 0.09% to 0.9%, about 0.09% to 0.8%, about 0.09% to 0.7%, about 0.09% to 0.6%, about 0.09% to 0.5%, about 0.09% to 0.4%, about 0.09% to 0.3%, about 0.09% to 0.2%, about 0.09% to 0.1%, about 0.01%, about 0.03%, about 0.05%, about 0.075%, about 0.08%, about 0.09%, about 0.1%, about 0.2% or about 0.3% leucine, but is not limited thereto.

[0061] In one example of the present invention, the liquid dosage form comprises about 0.05% mannitol, about 0.15% sorbitol, about 0.3% sucrose, about 1.5% trehalose, about 0.1% leucine, or a combination thereof.

[0062] In one embodiment of the present invention, the plasmid DNA in the liquid dosage form still maintains 90-100, 91-100, 92-100, 93-100 or 94-100 SC% after being stored at 2-8°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months.

[0063] In one embodiment of the present invention, the plasmid DNA in the above liquid dosage form still maintains 80-100, 81-100, 82-100, 83-100, 84-100, 85-100 SC% after being stored at a temperature of 15-30°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months. The above storage temperatures are 15-30°C, 16-30°C, 17-30°C, 18-30°C, 19-30°C, 20-30°C, 21-30°C, 22-30°C, 23-30°C, 24-30°C, 25-30°C, 15-28°C, 16-28°C, 17-28°C, 18-28°C, 19-28°C, 20-28°C, 21-28°C, 22-28°C, 23-28°C, 24-28°C, 25-28°C, 15-27°C, 16-27°C, 17-27°C, 18-27°C, 19-27°C, 20 -27°C, 21-27°C, 22-27°C, 23-27°C, 24-27°C, 25-27°C, 15-26°C, 16-26°C, 17-26°C, 18-26°C, 19-26°C, 20-26°C, 21-26°C, 22-26°C, 23-26°C, 24-26°C, 25-26°C, 15-25°C, 16-25°C, 17-25°C, 18-25°C, 19-25°C, 20-25°C, 21-25°C, 22-25°C, 23-25°C, 24-25°C or 25°C, but is not limited to this.

[0064] In another embodiment of the liquid dosage form of plasmid DNA of the present invention, the liquid dosage form further comprises about 0.001 to 0.3% mannitol, about 0.05 to 0.5% sorbitol, about 0.05 to 0.5% sucrose, about 0.15 to 3% trehalose, about 0.045-0.055% leucine or a combination thereof.

[0065] In one example of the present invention, the liquid dosage form may contain about 0.001 to 0.3%, about 0.005 to 0.3%, about 0.01 to 0.3%, about 0.02 to 0.3%, about 0.03 to 0.3%, about 0.04 to 0.3%, about 0.05 to 0.3%, about 0.001 to 0.25%, about 0.005 to 0.25%, about 0.01 to 0.25%, about 0.02 to 0.25%, about 0.03 to 0.25%, about 0.04 to 0.25%, about 0.05 to 0.25%, about 0.001 to 0.2%, about 0.005 to 0.25%, about 0.01 to 0.25%, about 0.02 to 0.25%, about 0.03 to 0.25%, about 0.04 to 0.25%, about 0.05 to 0.25%, about 0.001 to 0.2%, about 0.005 to 0.25%, about 0.005 to 0.25%, about 0.005 to 0 .2%, about 0.01 to 0.2%, about 0.02 to 0.2%, about 0.03 to 0.2%, about 0.04 to 0.2%, about 0.05 to 0.2%, about 0.001 to 0.15%, about 0.005 to 0.15%, about 0.01 to 0.15%, about 0.02 to 0.15%, about 0.03 to 0.15%, about 0.04 to 0.15%, about 0.05 to 0.15%, about 0.001 to 0.1%, about 0.005 to 0.1%, about 0.01 to 0.1%, about 0.02 to 0.1%, about 0.03 to 0.1%, about 0.0 4 to 0.1%, about 0.05 to 0.1%, about 0.001 to 0.075%, about 0.005 to 0.075%, about 0.01 to 0.075%, about 0.02 to 0.075%, about 0.03 to 0.075%, about 0.04 to 0.075%, about 0.05 to 0.075%, about 0.001 to 0.07%, about 0.005 to 0.07%, about 0.01 to 0.07%, about 0.02 to 0.07%, about 0.03 to 0.07%, about 0.04 to 0.07%, about 0.05 to 0.07%, about 0.001 to 0. 06%, about 0.005 to 0.06%, about 0.01 to 0.06%, about 0.02 to 0.06%, about 0.03 to 0.06%, about 0.04 to 0.06%, about 0.05 to 0.06%, about 0.001 to 0.05%, about 0.005 to 0.05%, about 0.01 to 0.05%, about 0.02 to 0.05%, about 0.03 to 0.05%, about 0.04 to 0.05%, about 0.01%, about 0.03%, about 0.05%, about 0.07%, about 0.075% or about 0.1% concentration of mannitol, but is not limited thereto.

[0066] In one embodiment of the present invention, the liquid dosage form comprises about 30-39mM, about 31-39mM, about 32-39mM, about 33-39mM, about 34-39mM, about 34-39mM, about 35-39mM, about 36-39mM, about 37-39mM, about 30-38.5mM, about 31-38.5mM, about 32-38.5m M, about 33-38.5mM, about 34-38.5mM, about 34-38.5mM, about 35-38.5mM, about 36-38.5mM, about 37-38.5mM, about 30-38mM, about 31-38mM, about 32-38mM, about 33-38mM, about 34-38mM, about 34-38mM, about 35-38mM, about 36-38mM, about 37-38mM, about 30-37.5mM, about 31-37.5mM, about 32-37.5mM, about 33-37.5mM, about 34-37.5mM, about 34-37.5mM, about 35-37.5mM, about 36-37.5mM, about 37-37.5mM, about 30-37.3mM, about 31 -37.3mM, about 32-37.3mM, about 33-37.3mM, about 34-37.3mM, about 34-37.3mM, about 35-37.3mM, about 36-37.3mM, about 37-37.3mM, about 36mM, about 37mM, about 37.3mM, about 37.5mM, about 38mM or about 39mM concentration of potassium phosphate.

[0067] In one embodiment of the present invention, the liquid dosage form comprises about 0.8-1.5%, about 0.85-1.5%, about 0.9-1.5%, about 0.95-1.5%, about 0.97-1.5%, about 0.975-1.5%, about 0.98-1.5%, about 0.8-1.25%, about 0.85-1.25%, about 0.9-1.25%, about 0.95-1.25%, about 0.97-1.25%, about 0.975-1.25%, about 0.98-1.25%, about 0.8-1.2%, about 0.85-1.2%, about 0.9-1.2%, about 0.95-1.2% , about 0.97-1.2%, about 0.975-1.2%, about 0.98-1.2%, about 0.8-1.1%, about 0.85-1.1%, about 0.9-1.1%, about 0.95-1.1%, about 0.97-1.1%, about 0.975-1.1%, about 0.98-1.1%, about 0.8-1.0%, about 0.85-1.0%, about 0.9-1.0%, about 0.95-1.0%, about 0.97-1.0%, about 0.975-1.0%, about 0.98-1.0%, about 0.8%, about 0.9%, about 0.95% or about 1.0% concentration of sodium chloride. But it is not limited thereto.

[0068] In one example of the present invention, the liquid dosage form comprises about 37 mM potassium phosphate, about 1.0% sodium chloride, about 0.05% mannitol, about 0.15% sorbitol, about 0.3% sucrose, about 1.5% trehalose, about 0.05% leucine or a combination thereof, and has a pH of about 8.0.

[0069] In this specification, the liquid dosage form according to one embodiment of the present invention is named as D dosage form.

[0070] In one embodiment of the present invention, the plasmid DNA in the above liquid dosage form still maintains 90-100, 91-100, 92-100, 93-100, 94-100, 95-100, 95-100, 96-100 SC% after being stored at a temperature of 2-8°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months.

[0071] In one embodiment of the present invention, the plasmid DNA in the above liquid dosage form still maintains 80-100, 81-100, 82-100, 83-100, 84-100, 85-100, 86-100, 87-100, 88-100 or 89-100 SC% after being stored at a temperature of 15-30°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months. The above storage temperatures are 15-30°C, 16-30°C, 17-30°C, 18-30°C, 19-30°C, 20-30°C, 21-30°C, 22-30°C, 23-30°C, 24-30°C, 25-30°C, 15-28°C, 16-28°C, 17-28°C, 18-28°C, 19-28°C, 20-28°C, 21-28°C, 22-28°C, 23-28°C, 24-28°C, 25-28°C, 15-27°C, 16-27°C, 17-27°C, 18-27°C, 19-27°C, 20 -27°C, 21-27°C, 22-27°C, 23-27°C, 24-27°C, 25-27°C, 15-26°C, 16-26°C, 17-26°C, 18-26°C, 19-26°C, 20-26°C, 21-26°C, 22-26°C, 23-26°C, 24-26°C, 25-26°C, 15-25°C, 16-25°C, 17-25°C, 18-25°C, 19-25°C, 20-25°C, 21-25°C, 22-25°C, 23-25°C, 24-25°C or 25°C, but is not limited to this.

[0072] In one example of the present invention, the above-mentioned liquid dosage forms (dosage forms A to D) according to one embodiment of the present invention suppress the change of plasmid DNA SC%.

[0073] In a specific example of the present invention, the SC% of the plasmid DNA contained in the above liquid dosage form composition is based on the initial measurement value, and after being stored at a temperature of 2-8° C. for at least 3 months, 4 months, 5 months or 6 months, it still maintains a measurement value of 80-100%, 85-100%, 90-100% or 95-100%. For example, in the case where the initial measurement value of the plasmid DNA SC% contained in the liquid dosage form composition of the present invention is 90 SC%, after being stored at a temperature of 2-8° C. for 6 months, the plasmid DNA SC% re-measured in the above liquid dosage form may be 72 SC% to 90 SC%. The above "initial measurement value" refers to the plasmid DNA SC% measured immediately after the plasmid DNA is added to the liquid dosage form of the present invention.

[0074] In other embodiments of the present invention, the plasmid DNA SC% contained in the above-mentioned liquid dosage composition is based on the initial measurement value and remains 70-100%, 75-100%, 80-100%, 81-100%, 82-100%, 83-100%, 84-100% or 85-100% of the measured value after being stored at a temperature of 15-30°C for at least 3 months, 4 months, 5 months or 6 months.

[0075] For example, when the initially measured value of SC% of plasmid DNA contained in the liquid dosage form composition of the present invention is 90 SC%, the SC% of plasmid DNA re-measured after storage at 30° C. for 6 months may be 63 SC% to 90 SC%.

[0076] The above storage temperatures are 15-30°C, 16-30°C, 17-30°C, 18-30°C, 19-30°C, 20-30°C, 21-30°C, 22-30°C, 23-30°C, 24-30°C, 25-30°C, 15-28°C, 16-28°C, 17-28°C, 18-28°C, 19-28°C, 20-28°C, 21-28°C, 22-28°C, 23-28°C, 24-28°C, 25-28°C, 15-27°C, 16-27°C, 17-27°C, 18-27°C, 19-27°C, 20 -27°C, 21-27°C, 22-27°C, 23-27°C, 24-27°C, 25-27°C, 15-26°C, 16-26°C, 17-26°C, 18-26°C, 19-26°C, 20-26°C, 21-26°C, 22-26°C, 23-26°C, 24-26°C, 25-26°C, 15-25°C, 16-25°C, 17-25°C, 18-25°C, 19-25°C, 20-25°C, 21-25°C, 22-25°C, 23-25°C, 24-25°C or 25°C, but is not limited to this.

[0077] In another embodiment of the present invention, the liquid dosage form is prepared in the form of a unit dose in the form of a vial, an ampule, a bottle or a pre-filled syringe.

[0078] The liquid dosage form of one embodiment of the present invention can be administered to a mammalian subject for the treatment of a variety of diseases. The liquid dosage form of the present invention can be administered by a variety of delivery methods, for example, oral or parenteral routes, for example, intravenous, intramuscular, intraendocardial, intramyocardial, intrapericardial, intraventricular, intraarticular, intradermal, intracerebral, intrarenal, intrahepatic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intramuscular, intramuscular, intraendocardial, intramyocardial, intrapericardial, intraventricular, intraarticular, intradermal, intracerebral, intrarenal, intrahepatic, intrasplenic ...splenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intrasplenic, intras In some embodiments, the drug may be administered by intravenous, intramuscular, intramyocardial, intrathoracic, intratracheal, intrathoracic, intradural, intraspinal, intramedullary, intramural, intrascorionic, and intraarterial injection or infusion or by rectal, intranasal, inhalational, or topical administration into the eyeball. In certain embodiments, the delivery method is intramuscular, intramyocardial, intravenous, intracerebral, or intrarenal.

[0079] In one example of the present invention, the nucleic acid construct is administered by injection of a liquid pharmaceutical composition. In a specific example, the polynucleotide construct is administered by intramuscular injection. Typically, the polynucleotide construct is administered to the affected part by intramuscular injection. In a portion of examples, the polynucleotide construct is administered to the muscles of the limbs, heart, or other body parts of the subject.

[0080] In some embodiments, the construct is injected subcutaneously or intradermally. In some embodiments, the polynucleotide construct is administered by intravascular delivery. In a specific embodiment, the construct is injected by retrograde intravenous injection.

[0081] It should be understood that the typical daily dosage of the composition of the liquid dosage form of the present invention should be determined with reference to a variety of relevant factors including the state to be treated, the selected route of administration, the age, sex and weight of the individual patient, and the severity of the patient's symptoms, and can be administered in a single dose or multiple doses. The polynucleotide construct is administered in a therapeutically effective amount.

[0082] In some examples of the methods described in this application, the polynucleotide construct is administered at a total dose of 1 μg to 200 mg, 1 mg to 200 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 20 mg, 5 mg to 10 mg, 16 mg, 8 mg or 4 mg.

[0083] In typical examples, the total dose is divided into multiple individual injection doses. In some examples, the total dose is divided into multiple identical injection doses. In some examples, the total dose is divided into different injection doses.

[0084] In the case of a divided dose, the total dose is administered at 4, 8, 16, 24 or 32 different injection sites.

[0085] In some examples, the injection dose is 0.1-5 mg. In specific examples, the injection dose is 0.1 mg, 0.15 mg, 0.2 mg, 0.25 mg, 0.3 mg, 0.35 mg, 0.4 mg, 0.45 mg or 0.5 mg.

[0086] The total administered dose may be administered during one visit or during two or more visits.

[0087] In a typical split dose example, all multiple injection doses are administered within 1 hour apart. In some examples, all multiple injection doses are administered within 1.5 hours, 2 hours, 2.5 hours or 3 hours apart.

[0088] In various embodiments of the present methods, the total dose of the polynucleotide construct need only be administered to the subject once, whether administered as a unitary dose or as divided into multiple injected doses.

[0089] In some examples, administration of a total dose of polynucleotide to multiple injection sites over one, two, three or four visits can include a single cycle. In particular, a single cycle of 32 mg, 16 mg, 8 mg or 4 mg of a polynucleotide construct administered to multiple injection sites over two visits can be included. The interval between the two visits can be 3 days, 5 days, 7 days, 14 days, 21 days or 28 days.

[0090] In some embodiments, the cycle can be repeated. The cycle can be repeated two, three, four, five, six or more times.

[0091] In some examples, the cycle can be repeated 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or more after the previous cycle.

[0092] In some examples, the total dose administered in the subsequent cycle is the same as the total dose administered in the previous cycle. In some examples, the total dose administered in the subsequent cycle is different from the total dose administered in the previous cycle.

[0093] In a currently preferred embodiment, the nucleic acid construct is administered at a dose of 8 mg in each affected limb, equally divided into multiple intramuscular injections and multiple visits, and multiple injections in any single visit are respectively performed at different injection sites. In a specific example, the nucleic acid construct is administered at a dose of 8 mg in each affected limb, equally divided into a first dose of 4 mg in each limb on day 0 and a second dose of 4 mg in each limb on day 14, wherein the first dose and the second dose are equally divided into multiple injection doses.

[0094] The actual amount, rate and duration of administration vary depending on the nature of the myopathy to be treated and the severity of the disease. In a typical example, the polynucleotide construct is administered in an amount effective to reduce the symptoms of the myopathy, for example, to reduce pain. In some examples, the amount is effective to reduce symptoms within 1 week of administration. In some examples, the amount is effective to reduce symptoms within 2 weeks, 3 weeks or 4 weeks after administration.

[0095] The plasmid DNA can be administered simultaneously or sequentially, alone or in combination with other plasmid DNAs, depending on the condition to be treated.

[0096] In some examples, the pharmaceutical composition in liquid dosage form contains plasmid DNA encoding human HGF. The pharmaceutical composition in liquid dosage form can be administered for the treatment of a variety of diseases, for example, diseases that have been shown in the past to be treatable by administering plasmid DNA. Plasmid DNA can encode therapeutic genes such as human HGF. These diseases include ischemic or liver disease, coronary artery disease (coronary artery disease, "CAD"), amyotrophic lateral sclerosis (amytrophic lateralsclerosis, "ALS"), peripheral artery disease (peripheral artery disease, "diabetic ulcer") and diabetic peripheral neuropathy (diabetic peripheral neuropathy, "DPN") or neuropathy caused by disease, trauma, infection or vitamin deficiency state, but are not limited to this. For example, neuropathy may be induced by diabetes, vitamin deficiency, autoimmune disease, hereditary or genetic disorder, amyloidosis, uremia, toxins or poisons, trauma or injury, tumors or may be idiopathic. The entire text of the references provided in this application is included in this application by reference.

[0097] [Effects of the invention]

[0098] The liquid dosage form containing plasmid DNA of the present invention exhibits excellent efficacy in terms of storage stability of plasmid DNA as a pharmaceutical active ingredient, and can be effectively used as a pharmaceutical composition having excellent product stability and safety.

Brief Description of the Drawings

[0099] Figure 1 It is a graph showing the results of testing the long-term stability of the liquid dosage form A of the present invention.

[0100] Figure 2a and Figure 2b This figure shows the results of explaining the influence of each factor through statistical processing in order to derive the liquid dosage form B and liquid dosage form C of the present invention (*KP=potassium phosphate, N=sodium chloride, MT=mannitol, SR=sucrose, TH=trehalose, LC=leucine).

[0101] Figure 3a and Figure 3b This is a diagram showing the results of statistical processing and interpretation in order to derive the optimal liquid dosage form of the present invention, and the derived composition.

[0102] Figure 4 and Figure 5 This figure shows the results of statistical processing interpretation in order to derive the optimal liquid formulation for improving the long-term stability of the plasmid DNA of the present invention.

[0103] Figure 6 This graph compares the stability of plasmid DNA when the liquid dosage form of the present invention is prepared in the form of a vial and a prefilled syringe in order to confirm whether the storage stability differs depending on the unit dosage form. [Specific implementation method]

[0104] [Example]

[0105] Throughout this specification, the "%" used to express the concentration of a specific substance is (weight / weight) %, solid / solid is (weight / volume) %, solid / liquid is (weight / volume) %, and liquid / liquid is (volume / volume) %.

[0106]

Table 1: Abbreviations

[0107] AVE Average BDP Bulk Drug Product CMO Contract Manufacturing Organization DNA Deoxyribonucleic Acid DP Drug Product DS Drug Substance GMP Good Manufacturing Practice HX Helixmith Co., Ltd. N / A Not Applicable OC% Open-Circular pDNA Configuration pDNA Plasmid DNA SC% Supercoil pDNA Configuration ALD Company A WBU W Company CB C Company

[0108] [Example 1. Development of Plasmid DNA Liquid Formulation A]

[0109] The present inventors screened the plasmid DNA liquid formulation A of the present invention 5 times in total. The component preparation, BDP preparation, vial filling, sampling and SC% analysis that can be used in the 5 screenings are all the same. The vials used in this example were washed according to the vial wash protocol up to 7 days before the preparation of the BDP formulation and stored in a 70°C dry oven before use. In the case of rubber stoppers, sterilization was completed at the vendor (West-DAIKYO SEIKO Co., Ltd.) and used in the test immediately after opening.

[0110]

BDP Preparation (Bulk Drug Product Formulation)

[0111] The 1X buffer and 2X buffer used in this example were prepared at least 7 days before the start of BDP preparation. In the case of the 2X buffer, no sodium chloride was added, and the buffer strength, mannitol, and sucrose concentration (conc.) were prepared in a manner of X2 (however, when the sodium chloride concentration of the final dosage form (Final Formulation) is 0.9%, the 2X buffer is also prepared with 0.9% sodium chloride, and when the sodium chloride concentration is 1.1%, the 2X buffer is prepared with 1.3% sodium chloride).

[0112] In the case of 1X buffer, the composition is the same as the final dosage form.

[0113] This experiment was conducted on a small scale buffer (100 mL) and the preparation error of the 1X and 2X buffers was ~2% in consideration of the preparation error of the actual commercial production process.

[0114] The API used in this test was VM202 DS (lot no. 88084) produced by Company A. It was moved from a -70°C deep freezer to a 2-8°C refrigerator and thawed for 20-24 hours before use.

[0115] The thawed DS was mixed with 2X and 1X buffers to prepare BDP with a final pDNA concentration of 0.48-0.52 mg / ml (target: 0.5 mg / mL).

[0116] The BDP preparation process and sampling & analysis steps are shown in Table 2 below.

[0117] [Table 2: BDP preparation and sampling steps]

[0118]

[0119]

[0120] The list of dosage forms used in the first to fifth rounds of screening is shown in Tables 3 to 7 below [Table 3: List of dosage forms used in the first round of screening]

[0121]

[0122]

[0123] [Table 4: List of dosage forms used in the second round of screening]

[0124]

[0125] [Table 5: List of dosage forms used in the third round of screening]

[0126]

[0127] [Table 6: List of dosage forms used in the fourth round of screening]

[0128]

[0129] The fourth round of screening was an experiment conducted twice, so P40 ctrl was prepared and analyzed twice.

[0130] [Table 7: List of dosage forms used in the fifth round of screening (long-term stability test)]

[0131]

[0132]

Screening analysis method

[0133] High temperature conditions accelerate the decomposition of pDNA SC%. In this example, after storing the liquid DP vial in an oven at 70°C, samples were taken on day 0, day 1, day 3, and day 5 and analyzed for SC% (by HPLC). Immediately after sampling, the analysis sample was stored in a deep freezer at -70°C, and thawed in a cold room at 2-8°C 1 hour before sample analysis and then analyzed by HPLC.

[0134] To reduce sample analysis time and cost, if the pDNASC% of a sample was less than 10%, no further samples taken after the relevant sample were analyzed.

[0135]

Long-term Stability Study

[0136] In order to confirm the long-term stability of the liquid dosage form, the inventors set the conditions of 2-8°C, 25°C, and 37°C and analyzed the SC% at intervals of one month to confirm the stability under various temperature conditions. The samples at 2-8°C were stored in a HX refrigerator set, the samples at 25°C were stored at room temperature, and the samples at 37°C were stored in a 37°C incubator.

[0137] In order to maintain the specified sampling conditions, a vial (5 ml filling) was sampled a maximum of 4 times and the final pH was measured and discarded.

[0138] All other conditions are the same as those in the first to fourth rounds.

[0139]

Screening analysis results

[0140] [Example 1-1. First round of screening (screening buffer, pH)]

[0141] The present inventors used VM202 pDNA as a raw material to set the type and pH range of a buffering agent that could be stably maintained.

[0142] First, in order to confirm the effects of various buffers, potassium phosphate, Tris, histidine, and sodium citrate were used as buffers.

[0143] The final dosage form list (List) was selected using the possible pH range in each buffer (but considering the literature data (Antoine Al-Achi, 2013), the pH was set within the range not exceeding pH 8.0).

[0144] The results of the first round screening SC% (by HPLC) analysis are shown in Table 8 below.

[0145] [Table 8: Results of the first round of screening (screening buffer, pH)]

[0146]

[0147]

[0148] The closer the pH value was to 8.0, the higher the VM202 pDNA SC% was, and it was most stable when potassium phosphate was used as a buffer.

[0149] Specifically, in PC8.0 and PD8.0, SC% remained above 30% during 3 days, and in PC7.4 and PD7.4, SC% also remained above 60% on the first day, but SC% dropped to about 10% on the third day, confirming that SC% stability was lower than that of PC8.0 and PD8.0.

[0150] Based on the above results, it was confirmed that, when the same buffer solution was used, the higher the pH, the more stable the SC% was maintained.

[0151] Furthermore, it was confirmed that the higher the buffer strength, the longer the pH was maintained during preparation (see the results of PC8.0, PD8.0, TC8.0, and TD8.0). Therefore, it was confirmed that when the same buffer was used, the higher the pH and buffer strength, the higher the stability of SC%.

[0152] The type of buffer also affects the stability of SC%, and it was confirmed that VM202 pDNA showed high stability in potassium phosphate buffer and sodium citrate buffer.

[0153] Based on the above results, it is determined that the most suitable buffer for the liquid formulation of VM202 is potassium phosphate buffer, pH 8.0.

[0154] [Example 1-2. Second round of screening (screening excipients)]

[0155] Based on the above first round screening results (potassium phosphate, pH 8.0), the optimal excipient concentration range that plays a role in pDNA stability was explored by treating mannitol and sucrose used as pDNA stabilizers at various concentrations.

[0156] The optimal buffer identified in the first round of screening was potassium phosphate, pH 8.0, as the basic composition.

[0157] The stability of pDNA was compared at various concentrations of mannitol and sucrose.

[0158] The results of the second round of screening SC% (by HPLC) analysis are shown in Table 9 below.

[0159] [Table 9: Second round screening results (screening excipients)]

[0160]

[0161] No significant difference in pDNA SC% was found in PMS0.1, PMS0.5, PMS1, and PMS2 over the 5 days. In addition, both PN45 and P20 / MS maintained SC% of more than 70% on the first day, but on the third day, PN45 showed a stable increase of SC% of more than 30% compared with P20 / MS.

[0162] Based on the above results, it was confirmed that the SC% of VM202 (a sample produced by Company A without good manufacturing practice (Non-GMP)) was not related to the concentrations of mannitol and sucrose (refer to the results of PMS0.1 and PMS2).

[0163] Furthermore, based on the result that the SC% on the third day of PN45 was about 30% higher than that of P20 / MS, it can be inferred that the buffer strength has a greater impact on the stability of pDNA SC% than the content of mannitol and sucrose (refer to the results of PN45 and P20 / MS pDNA SC%).

[0164] Therefore, it was determined that in the third round of screening, it was also possible to remove mannitol and sucrose from the dosage form composition.

[0165] [Example 1-3. The third round of screening (screening salt)]

[0166] Based on references that discuss that salt can maintain stability by neutralizing the negative charge of the phosphate group of pDNA during depurination, the inventors explored the optimal salt type and concentration range that play a role in the pDNA SC% stability of VM202.

[0167] Based on the results of the first and second rounds of screening, 40 mM potassium phosphate, 0.45% sodium chloride, pH 8.0 were used as the basic composition.

[0168] Based on academic data that salts such as sodium chloride and magnesium chloride affect the stability of pDNA, the present inventors conducted experiments using sodium chloride and magnesium chloride at various concentrations.

[0169] Finally, for intramuscular injection as the injection form of VM202, the concentration range of the salt is set in consideration of the injectable osmotic pressure (theoretically 280 to 360 mOsm / kg, preferably less than 600 mOsm / kg).

[0170] The results of the third round of screening SC% (by HPLC) analysis are shown in Table 10 below.

[0171] [Table 10: Results of the third round of screening (screening salt)]

[0172]

[0173]

[0174] VM202 pDNA confirmed that the pDNA SC% stability increased with increasing sodium chloride concentration (refer to the results of PN45 and PN9).

[0175] Furthermore, it was confirmed that the pDNA SC% stability increased significantly when the sodium chloride concentration was 0.9%.

[0176] In the case of magnesium chloride, when the sodium chloride content was 0.45%, an effect of increasing SC% of about 10% was shown, but it was confirmed that magnesium chloride was precipitated as magnesium hydroxide (Mg(OH) 2 ) by reacting with water over time.

[0177] It was confirmed that the maximum amount of magnesium chloride that can be dissolved in 40 mM potassium phosphate and 0.9% sodium chloride is 0.01%, and that magnesium chloride will precipitate at a concentration above that.

[0178] PN9M1 and PN9M5 precipitated magnesium chloride on the fifth day (HPLC analysis was completed).

[0179] When analyzing based on the above results, it was confirmed that the SC% stability increased significantly as the concentration of sodium chloride increased (refer to the results of PN45 and PN9).

[0180] In addition, in the case of magnesium chloride, when the concentration in aqueous solution is above a fixed level (PN45M condition), magnesium hydroxide is precipitated. This is because the condition used in this round is a high pH of 8.0, and due to the high (OH) - Therefore, it was confirmed that magnesium hydroxide could not improve the pDNA SC% stability when the salt concentration was higher than that of PN45M.

[0181] Based on the above results, when 0.9% sodium chloride was used as the salt alone, the pDNA SC% stability was the highest (baseline SC% on the fifth day: 44%). Based on the results of the third round of screening, the optimal composition of the liquid dosage form of VM202 pDNA (Company A) was judged to be 40mM potassium phosphate and 0.9% sodium chloride.

[0182] [Example 1-4. Round 4 Screening (Screening Double Buffer)]

[0183] The present invention aims to confirm whether the pDNA SC% when using two buffers (potassium phosphate and Tris) (double buffering agent) is more stable than when using only one buffer (potassium phosphate), and based on the results that the higher the pH, the more stable the pDNA is in the first to third rounds of screening, confirm whether the pDNA is more stable after the pH is increased by using two buffers (double buffering agent).

[0184] First, pDNA is prepared in a liquid dosage form by mixing two buffers at a ratio different from that of phosphate buffer and Tris buffer used in the past.

[0185] Based on the results of the first round of screening that the higher the pH, the more stable the pDNA was, phosphate and Tris were mixed to prepare a pH higher than pH 8.0 and then the stability of pDNA was tested.

[0186] Referring to the third round of screening results, the sodium chloride concentration was fixed at 0.9%.

[0187] The results of the fourth round of screening SC% (by HPLC) analysis are shown in Table 11 below.

[0188] [Table 11: Results of the fourth round of screening (double screening buffer)]

[0189]

[0190]

[0191] In the experiment where the pH was fixed at 8.0 and the ratio of phosphate to Tris was changed, it was confirmed that the higher the phosphate ratio, the more stable the pDNA was (refer to the results of P / T3:1 and P / T1:3). In the experiment where the ratio of phosphate to Tris was fixed and the pH was changed, it was confirmed that the higher the pH, the more stable the pDNA was.

[0192] Finally, when using Double buffer, it was confirmed that the pDNA stability at a phosphate to Tris ratio of 1:1 and pH 8.7 was similar to that at 40 mM phosphate and pH 8.0.

[0193] The fourth round of screening confirmed that the higher the phosphate ratio, the longer the stability of pDNA SC% could be maintained.

[0194] It was confirmed that when the ratio of phosphate to Tris was the same, the higher the pH, the more stable the pDNA.

[0195] Therefore, in the case of a double buffer formulation, it was confirmed that the higher the ratio of the phosphate buffer and the higher the pH of the formulation, the higher the stability of pDNA.

[0196] However, it was confirmed that the SC% stability of P40 and P / T8.7 was similar. This indicates that the pDNA SC% stability effect of the double buffer is not significantly different from that of the existing single buffer formulation. In addition, since the strength of each buffer is 40mM when using the double buffer, the osmotic pressure increases.

[0197] Therefore, based on the above results, it was determined that the existing single buffer, 40 mM phosphate, pH 8.0 was the optimal composition.

[0198] [Example 1-5. Fifth round of screening (Long-term stability of the final candidate group)]

[0199] The long-term stability of the 40 mM phosphate, 0.9% sodium chloride, pH 8.0 formulations selected from the first to fourth rounds of screening and additional lead candidates was confirmed at various temperatures.

[0200] In order to confirm the saturation point of the buffer and salt under the selected conditions of 40 mM phosphate, 0.9% sodium chloride, pH 8.0, long-term stability tests were performed by adding 60 mM phosphate, 0.9% sodium chloride / 100 mM phosphate, 1.1% sodium chloride.

[0201] It is preferred to sample and confirm at different time periods at 2-8°C as DP storage temperature, 25°C as accelerated conditions, and 37°C as stress conditions.

[0202] In order to maintain the specified sampling conditions, a vial (5 ml package) was sampled up to 4 times, and the remaining sample was discarded after the final pH was measured.

[0203] The plan for the long-term stability study is shown in Table 12 below.

[0204]

Table 12: Long-term stability test plan

[0205]

[0206]

[0207] The results of the fifth round of screening SC% (by high performance liquid chromatography) are shown in Table 13 and Figure 1 shown.

[0208] [Table 13: Fifth round of screening (long-term stability test of the final candidate group) SC% results]

[0209]

[0210] -N / A indicates not analyzed. It was confirmed that the compositions of P40, P60, and P100 showed similar SC% after storage under various temperature conditions.

[0211] It was confirmed that the SC% of P40 was 80% or more (or more than the acceptance criteria of VM202 DP) after storage at 25°C for 6 months.

[0212] Based on this, according to previous expectations, with the relevant composition, when stored at a temperature of 2-8°C, it was judged that it would be stable for more than 18 months. However, when it was actually stored at a temperature of 2-8°C for 6 months, it was confirmed that the SC% differed from the T0 time point by less than 1%.

[0213] Under the condition of 37°C, which is a severe (stress) condition, it was confirmed that the SC% was maintained at 80% for about 2 months.

[0214] The above results confirmed that the analysis results of SC% were similar under all conditions of P40, P60, and P100. This showed that the VM202 pDNA SC% stability of phosphate buffer strength and sodium chloride was maintained to the greatest extent under the conditions of 40 mM, 0.9%, and pH 8.0, and that sodium chloride or pH stability did not have a greater impact on SC%.

[0215] Therefore, based on the above results, it was determined that the formulation of P40 (pH 8.0, 40 mM phosphate, 0.9% sodium chloride) was the most suitable for the final formulation of VM202 DP.

[0216] [Conclusion of Example 1]

[0217] After four rounds of screening and one round of 6-month stability test, a VM202 liquid dosage form with the target stability (25°C, storage for three months, SC% above 80%) was successfully developed.

[0218] This example confirmed that VM202 pDNA stability is affected not only by pH but also by the type of buffer. Magnesium chloride, which is expected to maintain DNA more stably than sodium chloride according to academic data, precipitates as magnesium hydroxide and cannot play a role in maintaining DNA stability. This is believed to be because the pH of the VM202 formulation is relatively high, pH 8.0, which is different from academic data. Due to the high (OH) - ions to form magnesium hydroxide.

[0219] Furthermore, through a 6-month stability test, it was confirmed that the composition of VM202 pDNA in 40 mM phosphate buffer, 0.9% sodium chloride, pH 8.0 was stable (SC% 83%) even after storage at 25°C for 6 months.

[0220] If necessary, the storage stability of the final derived composition at 2-8°C will be confirmed through a long-term stability test (18 months), and the composition range suitable for future commercial production will be determined based on the final derived composition.

[0221] The composition finally derived through five rounds of screening in this Example 1 is shown in Table 14 below.

[0222] [Table 14: Final derived composition]

[0223]

[0224] The final derived composition (40 mM potassium phosphate, 0.9% sodium chloride, pH 8.0) was higher than the DP spec standard (89.5% SC) when stored at 25°C for 3 months, so it was determined that the dosage form was stable for more than 18 months under storage conditions of 2-8°C. It is intended to grasp the composition range that can be applied to future commercial production based on the final derived composition.

[0225] [Example 2: Development of Plasmid DNA Liquid Formulation B and Plasmid DNA Liquid Formulation C]

[0226] It was confirmed that when the composition of the liquid dosage form derived in Example 1 was applied to VM202 DS produced by Company C, Company W, and Helixmith, the SC% stability was different from that of VM202 DS produced by Company A. Therefore, this experiment was conducted to expand the boundaries of the liquid dosage form limited to VM202 DS produced by Company A. The liquid dosage form applicable to VM202 DS of Company A established in Example 1 was named Liquid Formulation A.

[0227] As in the previous embodiment, the stability of VM202 DP is evaluated by the SC% ratio which is one of the factors determining the quality of VM202.

[0228] It was determined that the basic characteristics of VM202 DS were the same, and therefore, the screening of this example was performed based on the composition of the liquid dosage form A selected in the above Example 1.

[0229] Liquid formulation B (Formulation B) was selected with reference to the screening results of liquid formulation A, and liquid formulation C (Formulation C) having the optimal concentration of each excipient was selected through DoE.

[0230] The stability target of this screening is to maintain the DP Spec (SC% 85%) standard at 20-25°C for more than 3 months. The relevant target setting is based on the research that the higher the storage temperature, the faster the decomposition of pDNA SC%, and it is selected based on the assumption that if it is stable for 3 months at 20-25°C, it will be stable for more than 18 months at 2-8°C, which is the DP storage temperature.

[0231] In addition, in order to shorten the development time, pDNA was exposed to 70°C for 5 days (accelerated conditions) to promote the pDNA decomposition rate and then the SC% was analyzed. For the long-term stability test, samples were taken in units of 2 weeks (1 month at 2-8°C) after storage at 2-8°C, 20-25°C, and 37°C, and the SC% was measured over a period of 3 months (3 years at 2-8°C).

[0232] Similar to Example 1, the four rounds of screening in this example were carried out in the process of ingredient preparation, BDP preparation, vial packaging, sampling and SC% analysis.

[0233] The vials used in the test were similar to the actual production process to the greatest extent possible. They were cleaned according to the vial cleaning plan and stored in an oven at 70°C up to 2 days before the preparation of the BDP formulation. In the case of rubber stoppers, they were sterilized at the vendor (West-DAIKYO SEIKO Co., Ltd.) and used in the test immediately after opening.

[0234] Preparation of dosage form

[0235] The 1X buffer and 2X buffer used in this example were prepared at most 3 days before starting each round of BDP preparation.

[0236] In the case of 2X buffer, the buffer strength, mannitol, sucrose, sorbitol, trehalose, leucine, and arginine concentrations are prepared in a manner of X 2 (however, the sodium chloride concentration is based on the sodium chloride concentration (A) of the final composition and is calculated by substituting the value into the following formula. * (A×2)-0.9=sodium chloride concentration of 2X buffer).

[0237] The 1X buffer has the same composition as the final dosage form.

[0238] This example is a small-scale buffer (100 mL) preparation. Considering the preparation error in the actual commercial production process, the preparation error range of 1X and 2X buffers is ∼2%.

[0239] The API used in this example was VM202 DS (lot no. 88084) produced by Company A, VM202 DS (lot no. 2017#0042U) produced by Company C, VM202 DS produced by Helixmith, and VM202 DS (lot no. DEV19-035049061068) produced by Company W. The samples were moved from a -70°C deep freezer to a 2-8°C refrigerator and thawed for 20-24 hours before use.

[0240] The thawed DS was mixed with 2X and 1X buffer to prepare BDP with a final pDNA concentration of 0.48-0.52 mg / ml (target 0.5 mg / mL).

[0241] The BDP preparation process, sampling and analysis steps are shown in Table 15 below.

[0242] [Table 15: BDP preparation and sampling process]

[0243]

[0244] The list of dosage forms used in the first to fourth rounds of screening is shown in Tables 16 to 21 below.

[0245] [Table 16: First round pre-screening list 1 (excipients)]

[0246]

[0247] In the previous example of liquid dosage form A, potassium phosphate was selected as the optimal buffer for liquid dosage form development. In this example, the buffer was fixed to potassium phosphate.

[0248] [Table 17: First round pre-screening list 2 (arginine)]

[0249]

[0250]

[0251] [Table 18: First round pre-screening list 3 (Range)]

[0252]

[0253] [Table 19: Design of Experiment (DoE) (DOE; Random Design) for the second round of experiments]

[0254]

[0255]

[0256] [Table 20: The third round of long-term stability test and comparative formulation list A (Long-term Stability Study of Formulation B, Formulation C and Comparison Formulation A)]

[0257]

[0258]

[0259] Table 21: Fourth round of scale-up process adjustment

[0260]

[0261] After the preparation of BDP, the pH was adjusted to 8.0 and filtered using a Supor EKV-Mini Kleenpak capsule filter (Pall Co., LTD), and then dispensed into vials (aliquot).

[0262] Analysis

[0263] High temperature accelerates the degradation of pDNA SC%. In this experiment, after storing the Liquid DP vials in an oven at 70°C, samples were taken on the 0th day and the fifth day to analyze the sample SC% (by high performance liquid chromatography) (in the case of Round 3, samples were taken on the 0th day, the first day, the third day, and the fifth day).

[0264] After sampling and analysis, the samples were immediately stored in a deep freezer at -70°C, and thawed in a refrigerator at 2-8°C 1 hour before sample analysis before HPLC analysis.

[0265] To reduce sample analysis time and cost, if the pDNA SC% of a sample was less than 10%, no further samples taken after the relevant sample were analyzed.

[0266]

Long-term stability test

[0267] In order to confirm the long-term stability under various temperature conditions, the conditions were set at 2-8°C, 20-25°C, and 37°C, and samples were taken at intervals of 2 weeks (1 month at 2-8°C) to analyze the SC%.

[0268] The samples at 2-8℃ were stored in the HX cold storage room, the samples at 25℃ were stored at room temperature in the No. 530 laboratory, and the samples at 37℃ were stored in a 37℃ constant temperature box.

[0269] In order to make the sampling conditions consistent, a maximum of 200ul was taken from a vial (5ml package) each time, and the sample was discarded after five times of sampling.

[0270]

Scale-up process adjustment study

[0271] The pDNA SC% stability was confirmed by scaling up from a small scale (~15 ml BDP) process to a large scale (150 ml BDP) process. The method for confirming the SC% stability was the same as in Example 1.

[0272] In order to confirm whether the presence or absence of a filtration process in the compositions of liquid formulations A and C affects the stability of pDNA SC%, an experiment was conducted with and without the use of a filter after the preparation of BDP.

[0273] [Example 2-1. First round of screening (excipients)]

[0274] Considering that the efficacy of the composition of liquid dosage form A established in Example 1 is limited to the DS of Company A, it is intended to develop a composition that has stability similar to that of liquid dosage form A + DS of Company A in VM202 DS produced by other CMOs such as Company C or Company W. To this end, it is intended to confirm the types and concentration ranges of excipients that can increase the SC% stability in VM202 pDNA produced at various production sites other than Company A by adding various excipients.

[0275] Experimental design

[0276] In order to confirm the effects of various excipients, mannitol, sucrose, sorbitol, trehalose, leucine, and arginine were treated at appropriate different concentrations and the significant range was confirmed.

[0277] The concentration range of each excipient was selected after considering the investigation of the component of biosimilars data approved by the US Food and Drug Administration (FDA) (Reference Index) and literature data (Rev Bras Otorrinolaringol, 2006; 72(3): 400-6).

[0278]

result

[0279] The results of the osmotic pressure and SC% (by HPLC) analysis of the first round of pre-screening 1 to 3 are shown in Tables 22 to 24 below.

[0280] [Table 22: Results of the first round of pre-screening 1 (excipients)]

[0281]

[0282] In Prescreening 1 to Prescreening 3, osmotic pressure was measured only in Prescreening 1, taking into account the duplication of each excipient concentration.

[0283] When mannitol was included (similar results were obtained at 0.5% and 1.5%), VM202 pDNASC% tended to increase as the concentration of sucrose or trehalose increased or the pH increased (see the results of A005).

[0284] [Table 23: Results of the first round of pre-screening 2 (arginine)]

[0285]

[0286] Pre-screening 2 was conducted at a sodium chloride concentration of 0.38%. The purpose of this pre-screening 2 was to confirm whether the increase in SC% stability of A005 confirmed in pre-screening 1 was due to the pH increase caused by arginine or the effect of arginine itself.

[0287] In order to confirm the above, the group with additional arginine (0.0025%) and the group without arginine were divided into two groups based on the existing excipients, and the pH was adjusted to 8.0 (eliminating the effect of pH increase) to confirm the SC% increase effect of arginine itself. The results confirmed that the addition of arginine did not increase the stability of SC%.

[0288] It was confirmed that the increase in SC% stability of A005 confirmed in Pre-screening 1 was due to the increase in pH, and arginine itself had no effect. Therefore, arginine was removed from the subsequent dosage form composition.

[0289] [Table 24: Results of the first round of pre-screening 3 (range)]

[0290]

[0291] In pre-screening 3, in order to confirm stability under slightly harsh conditions, the conditions were pH 7.9. When compared with the liquid dosage form A composition (Control) as the control condition, M025 showed the highest level of increase in SC%, and other excipients also confirmed significant increases in SC% stability.

[0292]

Discussion

[0293] Among the added excipients, mannitol showed the highest SC% increase effect, and it was confirmed that the increase in SC% was similar in the range of 0.25-1.5% of mannitol added. The effect of mannitol reached saturation at 0.25%, and the mannitol concentration range of the DoE experiment was set to 0.05-0.25%.

[0294] Furthermore, a liquid formulation B (Formulation B) in which only 0.25% of mannitol was added to the composition of the existing liquid formulation A (Formulation A) was selected for comparison with the composition of the liquid formulation C (Formulation C) developed by DoE.

[0295] The concentration ranges of the remaining excipients were set by finding the saturation point (maximum 1.5%) using the same principle. Considering that in the case of sorbitol and leucine, the lower the concentration, the higher the SC%, the concentrations were set in the ranges of 0.05-0.25% and 0.1-0.5%, respectively.

[0296] Additionally, it was confirmed that disaccharides such as sucrose and trehalose can maintain pH buffering more stably than monosaccharides such as mannitol and sorbitol.

[0297] In summary, the above results showed that the possibility of developing new dosage form compositions that can be applied to VM202 DS produced at other production sites such as Company C and Company W was confirmed by adding additional excipients to the composition of the existing dosage form A, which is limited to VM202 DS produced by Company A. In addition, the efficiency of the DoE experiment was maximized by setting the concentration range in which each excipient affects the SC% stability.

[0298] [Example 2-2. Second round of experimental design (Design of Experiment, DoE)]

[0299] Using the candidate set of excipients and their concentration ranges selected in the first round of pre-screening, the optimal excipient composition for stabilizing VM202 pDNA was selected by DoE.

[0300] Experimental design

[0301] Based on the pDNA stability enhancing effects of various excipients identified in the first round of excipient screening, the stability of pDNA was compared in various combinations of concentration ranges to identify the effects of mutual combinations and the main excipient factors.

[0302] The DOE was performed with a randomized design and replicated twice.

[0303] The excipients confirmed by DOE are as follows:

[0304] Mannitol, sucrose, sorbitol, trehalose, leucine.

[0305] The results of the SC% (by HPLC) analysis of the second round of DOE are shown in Table 25 below.

[0306]

Table 25: Results of the second round of experimental design

[0307]

[0308]

[0309] The above result data (DATA) explained by statistical processing are as follows Figure 2a and Figure 2b shown. Figure 2a The results of an experiment conducted by statistical design to confirm the influence of changes in 7 factors (KP to LC) on the %SC of pDNA are shown. When p=0.05 is used as the statistical hypothesis test standard, it can be confirmed that all the main factors except MT and TH have a direct influence on %SC, and pH*MT and TH*TH have an influence on %SC as effect and square factors. Specifically, it is determined that within the selected range, the higher the KP (potassium phosphate), N (sodium chloride), and pH, the greater the pDNA stability.

[0310] In the case of SR (sucrose) and LC (leucine), it was determined that the lower the concentration within the selected range, the greater the pDNA stability.

[0311] In the case of MT (mannitol), it is considered that due to the interaction with pH, ​​when the pH value is high and the concentration of MT is low, the pDNA stability is increased to the greatest extent.

[0312] The model equation derived from this reflects the impact of each factor on %SC as follows: Figure 2b shown.

[0313] Based on the above explanation, the optimal composition is derived as follows Figure 3a and Figure 3b shown.

[0314]

Discussion

[0315] like Figure 3a As shown in the figure, there are seven factors affecting %SC, namely KP, N, pH, MT, SR, TH and LC. The best model derived from these factors is Solution 1. By using the model of Solution 1 and solving the equation statistically, it is possible to estimate the range of the average value distribution of the %SC statistical value at a 95% statistical value reliability level, which is about 19.209 to 22.845. In addition, it is predicted that each %SC value will be distributed between 17.451 and 26.603 at a 95% reliability level.

[0316] Among the three compositions derived from the above results using data, composition No. 1 (scheme 1) having the highest SC% was selected.

[0317] Furthermore, the present inventors determined the concentration or value of each factor within the range of each factor in a direction that can maximize the y value, that is, the %SC ( Figure 3b ).

[0318] In the case of sorbitol, since the DOE results showed that sorbitol had little effect on the pDNA SC% stability, it was fixed at a median value of 0.15% in the sorbitol conditions of the DOE.

[0319]

Dosage Form C

[0320] VM202 DS 0.5mg / mL Potassium Phosphate 40mM Sodium chloride 0.9% Mannitol 0.05% sucrose 0.3% Sorbitol 0.15% Trehalose 1.5% Leucine 0.1%

[0321] Example 2-3. Preparation of Liquid Formulation C (Formulation C: 40 mM potassium phosphate, 0.9% sodium chloride, pH 8.0, 0.05% mannitol, 0.15% sorbitol, 0.3% sucrose, 1.5% trehalose, 0.1% leucine) and Comparison of Formulation A, Formulation B, and Formulation C (Long-term Stability Test at 70°C)

[0322] In order to confirm the stability of the composition of the relevant liquid dosage form C under refrigerated conditions (2-8°C), room temperature storage conditions (20-25°C), and harsh conditions (37°C), a long-term stability test was conducted.

[0323] Confirm the long-term stability of the pDNA composed of liquid dosage form B and liquid dosage form C selected through previous screening, as well as the pDNA stability of the combination of VM202 DS production site and liquid dosage form A, liquid dosage form B, and liquid dosage form C.

[0324] Experimental design

[0325] The first round of pre-screening confirmed that mannitol as a single excipient had the greatest pDNA stabilization effect.

[0326] The composition of liquid dosage form B, in which only 0.25% of mannitol was added to the composition of the existing liquid dosage form A, and the composition of liquid dosage form C developed through DoE were applied to two lots of VM202 DS produced by HX Company and W Company to be compared with liquid dosage form A as the existing control condition.

[0327] The long-term stability test of liquid dosage forms A, B, and C at 70°C was conducted to confirm the SC% by sampling on day 0, day 1, day 3, and day 5.

[0328] The test plan for the third round of long-term stability test is shown in Table 26.

[0329] [Table 26: Polarization of the third round of long-term stability test (liquid dosage form B and liquid dosage form C)]

[0330]

[0331]

[0332] - Time point T0.5 = 0.5 month (2 weeks).

[0333] result

[0334] The results of the SC% analysis (by HPLC) of the third round of experiments are shown in Tables 27 and 28 below.

[0335] [Table 27: Comparison of Formulation A, B, C at 70°C in the third round]

[0336]

[0337] [Table 28: The third round of long-term stability test (Formulation B and Formulation C)]

[0338]

[0339]

[0340] - In the case of the first, third, and fifth day samples and the samples at 2-8°C, only a portion of the samples were analyzed. - If the relevant sample could not be analyzed, it is indicated as N / A.

[0341] As can be confirmed in Table 27, in the fifth day results of liquid dosage form C at 70°C, liquid dosage form C showed similar stability in DS produced by HX, W Company, and ALD (average SC was 20.6%), while in the case of liquid dosage form B, in A Company (SC 6.6%), it was confirmed that liquid dosage form A had an overall lower SC% (9.8%) stability.

[0342] This is also similar in the long-term stability results in Table 28. It was confirmed that at 37°C in the 12th week, liquid dosage form C showed an SC% of 60.0-70.5% in all batches of DS of HX and W companies. In contrast, liquid dosage form B showed a large difference between DS batches at 29.0-72.0%.

[0343] In the long-term stability results at 25°C, the average SC% after 6 months was 79.4% for Liquid Formulation C and 75.7% for Liquid Formulation B, and it was confirmed that VM202 pDNA was more stably maintained in Liquid Formulation C.

[0344]

Discussion

[0345] Based on the above analysis of the results, it was determined that compared with liquid dosage form B, liquid dosage form C, which was a composition developed by DoE, had less variation between DS batches and more stably maintained VM202pDNASC% at room temperature (20-25°C).

[0346] In the case of Liquid Formulation C, even under the condition of maintaining SC% of 85% or more when stored at 25°C for 3 months, which is the target of the relevant test (average of 86.7% when stored for 3 months).

[0347] Therefore, through the third round of screening, liquid dosage form C was successfully developed as a liquid dosage form that can be applied to VM202 DS produced by HX, W Company, etc., instead of the liquid dosage form limited to VM202 DS produced by Company A.

[0348] Additionally, since all the above experiments were conducted on a small scale, it was intended to confirm whether the relevant results could be reproduced under scaled-up conditions.

[0349] [Example 2-4. Fourth round of expansion process adjustment (Scale-up A, C)]

[0350] In order to confirm whether the composition of the liquid dosage form C developed through the first to third rounds can be directly applied under scale-up conditions and to confirm the presence or absence of SC% stability along with the filtration process, the following test was performed.

[0351] Experimental design

[0352] The liquid dosage form process previously performed at 20 mL scale was scaled up to 300 mL scale.

[0353] In order to confirm the influence of the filtration process, the prepared 300 mL of BDP was divided into 150 mL each, 150 mL was filtered (Filtration), and the other 150 mL was placed in a small bottle without filtration for rigorous testing.

[0354] The above process was applied to Liquid Formulation C and Liquid Formulation A to confirm the impact of errors in the scale-up and filtration processes in each case.

[0355] The 70°C severe test for the fourth round of scale-up process adjustment was sampled on day 0, day 1, day 3, and day 5 to confirm the SC%.

[0356]

result

[0357] The results of the fourth round of screening SC% (by HPLC) analysis are shown in Table 29 below.

[0358]

Table 29: Adjustments to the Fourth Round of Expansion Process

[0359]

[0360] As can be confirmed in Table 29, it was confirmed that the liquid dosage form C maintained a constant SC% regardless of the presence or absence of the filtration process. In contrast, the liquid dosage form A, when the filtration process was used, had a SC% of 8.9% on the third day, and the pDNA SC% was significantly different by more than 30% compared to the case without the filtration process (40.6%).

[0361]

Discussion

[0362] In the actual production process, a filtration process is required due to bioburden or sterility issues. Therefore, it is necessary to develop a liquid dosage form that can be applied with the filtration process.

[0363] Through the relevant rounds of testing, it was confirmed whether the SC% was stably maintained when the filtration process was applied to the liquid dosage form C (on the contrary, it was confirmed that the SC% stability could not be maintained when the filtration process was applied to the liquid dosage form A).

[0364] Therefore, through the relevant embodiments, a liquid dosage form C was successfully developed as a liquid dosage form that can be used in an actual production process.

[0365] [Conclusion of Example 2]

[0366] Through a total of four rounds of screening and forming, VM202 DS was developed that can be used in various production sites (first round, second round), VM202 liquid dosage form that meets the target SC% stability of relevant tests (third round), and VM202 that can be used in actual production processes (fourth round).

[0367] The results of the long-term stability of liquid dosage form C at 25°C (round 3) confirmed that the average SC% at week 12 was 86.7%, exceeding the target of 85%.

[0368] Furthermore, this example confirmed that the stability of VM202 pDNA varies with the production environment and batches, and the presence or absence of a filtration process also affects the stability of pDNA. Therefore, when introducing liquid dosage forms into actual production in the future, no matter what process VM202 DS is produced through, the material of the filter introduced or the process time (Process Time) should be considered as factors that ultimately affect the stability of DP.

[0369] If necessary, the storage stability of the liquid dosage form C at 2-8°C as the final derived composition is to be confirmed by a long-term stability test (36 months), and the composition range that can be used in industrial production in the future is to be determined based on the final derived composition.

[0370] The compositions derived through four rounds of experiments are shown in Table 30 below.

[0371] [Table 30: Final derived composition]

[0372]

[0373]

[0374] Liquid dosage form C (40 mM potassium phosphate, 0.9% sodium chloride, pH 8.0, 0.05% mannitol, 0.3% sucrose, 0.15% sorbitol, 1.5% trehalose, 0.1% leucine) with the final derived composition constructed by DoE showed stability (86.7% SC) over 3 months under the storage condition of 20-25°C according to the DP spec standard, and it was judged that the dosage form was stable for more than 18 months under the storage condition of 2-8°C.

[0375] It is intended to develop a composition that can be used in subsequent commercial production based on the final derived composition.

[0376] [Example 3: Development of Plasmid DNA Liquid Formulation D]

[0377] It was confirmed that when the compositions of liquid dosage forms B and C derived from Examples 1 and 2 were applied to VM202 DS produced by W Company and Helixmith, a liquid dosage form having a stability considerably higher than that of a freeze-dried dosage form was developed.

[0378] In this example, an experiment was conducted using the RSM (reaction surface modeling) method to derive the most stable optimal composition in VM202 from the composition of liquid dosage form C, and the optimal liquid dosage form derived by RSM was named liquid dosage form D.

[0379] As in the previous embodiment, the stability of VM202 DP is evaluated by determining the SC% ratio, which is one of the factors that determine the quality of VM202.

[0380] This study was conducted by improving the composition of liquid dosage form C to confirm the main effects, interactions, and curvature effects between the factors of each composition, and this experiment was conducted in a manner to derive the optimal composition through improvement and apply it.

[0381] In the previous examples, a liquid dosage form C having an optimal concentration of each excipient was selected by DoE, and the composition was additionally improved in consideration of the interactions between the factors confirmed by the liquid dosage form C.

[0382] The stability target of this test is to maintain the DP Spec (SC% 85%) standard for more than 3 months under storage conditions of 20-25°C. The relevant target is set based on the research that the higher the storage temperature, the faster the pDNA SC% decomposition. If it is stable for 3 months at 20-25°C, it is selected to be stable for more than 18 months at 2-8°C, which is the DP storage temperature.

[0383] Liquid dosage form D with improved composition was subjected to long-term stability test with liquid dosage form C as control. Samples were taken at 2-8°C for 4 weeks and at 20-25°C and 37°C for 2 weeks after storage to measure SC% over a 3-month period (planned for 3 years at 2-8°C).

[0384] The test sequence (Workflow) is shown in Table 31 below.

[0385] [Table 31: Test sequence]

[0386]

[0387]

[0388] [Test Summary]

[0389] The three rounds of screening conducted in this study were carried out with the same components preparation, BDP formulation, vial packaging, sampling, and SC% analysis procedures.

[0390] The vials used in the test were similar to the actual production process to the greatest extent possible. They were cleaned according to the vial cleaning plan and stored in an oven at 70°C up to 2 days before the preparation of the BDP formulation. In the case of rubber stoppers, they were sterilized at the vendor (West-DAIKYO SEIKO Co., Ltd.) and used in the test immediately after opening.

[0391]

preparation

[0392] The 1X buffer and 2X buffer used in the experiment were prepared up to 3 days before starting each round of BDP formulation.

[0393] In the case of 2X buffer, the buffer strength, mannitol, sucrose, sorbitol, trehalose, leucine, and arginine concentrations are prepared in a manner of × 2 (however, the sodium chloride concentration is based on the sodium chloride concentration (A) of the final composition and is calculated by substituting the value into the following formula. *(A×2)-0.9=sodium chloride concentration of 2X buffer).

[0394] The 1X buffer has the same composition as the final dosage form.

[0395] This example is a small-scale buffer (100 mL) preparation. Considering the preparation error in the actual commercial production process, the preparation error range of 1X and 2X buffers is ∼2%.

[0396] The API used in the experiment was VM202DS (batch: 8) produced by Company A, Company C, and Helixmith itself. th ,9 th ), VM202 DS produced by W Company (W Company 1: 1912063, W Company 2: 1912073) samples were moved from a -70°C deep freezer to a 2-8°C refrigerator and thawed for 16-18 hours before use.

[0397] The thawed DS was mixed with 2X and 1X buffer to prepare BDP with a final pDNA concentration of 0.48-0.52 mg / ml (target 0.5 mg / mL).

[0398] The BDP preparation process, sampling and analysis steps are shown in Table 32 below.

[0399] [Table 32: BDP preparation and sampling process]

[0400]

[0401]

[0402] The list of RSM formulations used in the first round of screening is shown in Table 33 below.

[0403]

Table 33: First round trial design (RSM)

[0404]

[0405] The compositions of liquid formulation C and liquid formulation D used in the second round of long-term stability testing are shown in Table 34 below.

[0406] [Table 34: List of long-term stability dosage forms in the second round]

[0407]

[0408]

[0409]

analyze

[0410] High temperature accelerates the deterioration of pDNA SC%, and after storing the liquid DP vials in an oven at 70°C, samples were taken on day 0 and day 5 to analyze the SC% of the samples (by high performance liquid chromatography). After sampling and analysis, the samples were immediately stored in a deep freezer at -70°C, and thawed in a refrigerator at 2-8°C 1 hour before sample analysis before HPLC analysis.

[0411]

Long-term stability test

[0412] In order to confirm the long-term stability under various temperature conditions, the conditions were set at 2-8°C, 20-25°C, and 37°C, and samples were taken according to the sampling plan described in Table 36 to analyze the SC%.

[0413] The samples at 2-8℃ were stored in the HX cold storage room, the samples at 25℃ were stored at room temperature in the No. 530 laboratory, and the samples at 37℃ were stored in a 37℃ constant temperature box.

[0414] In order to make the sampling conditions consistent, a maximum of 100ul was taken from a vial (5ml package) each time, and the sample was discarded after 10 times of sampling.

[0415]

Test results and discussion

[0416] [Example 3-1: First round of experimental design (RSM; reaction surface design)]

[0417] The reaction surface design was designed to obtain the optimal composition of each factor that plays a role in pDNA stability using the formulation C developed in previous studies. This was done with the purpose of confirming the optimal composition and combination that can be derived by confirming the main effects, interactions, curvature effects, etc. between various factors such as each excipient and buffer, pH, and salt.

[0418] Experimental design

[0419] The balance of the final composition of the liquid dosage form C derived in Examples 1 and 2 and the degree of influence of each factor on stability were confirmed.

[0420] The final composition is improved by using the acquired data and taking into account the interactions between the factors that can be identified when designing RSM, thereby obtaining a combination of factors that can be applied in terms of pDNA stability, that is, the optimal composition.

[0421] The goals for the optimal composition to be confirmed by DOE are as follows:

[0422] Potassium phosphate, sodium chloride and leucine.

[0423] The results of the SC% (by HPLC) analysis using the first round experimental design (RSM) are shown in Table 35 below.

[0424] [Table 35: Results of the first round of experimental design (RSM)]

[0425]

[0426]

[0427]

result

[0428] The above results and data explained by statistical processing are as follows Figure 4 and Figure 5 shown.

[0429]

Discussion

[0430] Figure 4 This is a graph showing the effects of factors used in pDNA preparation (e.g., potassium phosphate, sodium chloride, pH, etc.) on %SC. Figure 4 , it can be seen that the remaining factors except SB have a predetermined influence on %SC. When considering the degree of visual evaluation, potassium phosphate (KP), sodium chloride (N), and leucine (LC) can be regarded as factors that have a particularly strong influence. Therefore, these three factors are used in the optimization of the dosage form designed by RSM, and the remaining excipients except these three factors are the optimal composition obtained by DOE of liquid dosage form C in previous studies, and therefore, are the same as the composition of liquid dosage form C.

[0431] The composition of the remaining excipients is optimally selected based on whether there are main effects or interactions between the factors.

[0432] Figure 5 The effect of changing the concentration of sodium chloride and KP on %SC is shown after fixing leucine at 0.06%. Figure 5 As shown, it can be seen that as the concentration of sodium chloride (N) increases and the concentration of potassium phosphate (KP) decreases, the %SC increases. Specifically, it can be confirmed that when the leucine (LC) value is 0.06%, the optimal concentration ranges of potassium phosphate (KP) and sodium chloride (N) are 37.0-37.3 mM and 0.975-1.0%, respectively. Therefore, based on this, the upper limit of leucine is set to 0.055%, and the final concentration is set to 0.05% (leucine range: 0.045-0.055%).

[0433] The composition of the final derived liquid dosage form D is as follows.

[0434] Liquid Formulation D: 37 mM potassium phosphate, 1.0% sodium chloride, pH 8.0, 0.05% mannitol, 0.15% sorbitol, 0.3% sucrose, 1.5% trehalose, 0.05% leucine.

[0435] [Second round of long-term stability test (liquid dosage form D)]

[0436] [Test Summary]

[0437] This experiment was conducted to confirm the long-term stability of pDNA in the liquid formulation D composition selected by the previous DOE and to compare it with the long-term stability of pDNA in the liquid formulation C.

[0438] Experimental design

[0439] The composition of the existing liquid formulation C was obtained by modifying the concentrations of potassium phosphate, sodium chloride, and leucine, and the composition of the liquid formulation D was used for comparison with the liquid formulation C as the control composition.

[0440] Liquid Formulations C and D were tested at 2-8°C for 4 weeks and at 20-25°C and 37°C for 2 weeks to measure SC% over a 3-month period (2-8°C for 2 years).

[0441] The experiment used 4 batches of DS, including 2 batches of DS from HX and 2 batches of DS from W Company.

[0442] The test plan for the second round of long-term stability testing is shown in Table 36 below.

[0443] [Table 36: Second round of long-term stability test plan (dosage form D, dosage form C)]

[0444]

[0445]

[0446] - Time point T0.5 = 0.5 month (2 weeks).

[0447]

Test results

[0448] The results of the SC% analysis (by HPLC) of the second round of testing are shown in Table 37 below. [Table 37: Results of the second round of long-term stability testing (Formulation D, Formulation C)]

[0449]

[0450]

[0451] - Liquid formulation D (HX1, 25°C) was dropped in the fourth week, and liquid formulation C (HX1, 25°C) was dropped in the sixth week.

[0452] [Table 38: Second round of long-term stability test results (%SC average)]

[0453]

[0454] As can be confirmed in Table 38, the results of the liquid dosage form C at 20-25°C in the 24th week showed an average SC stability of 84.1%, whereas the results of the liquid dosage form D at 20-25°C in the 24th week showed an SC stability of 89.8%. In addition, it was confirmed that the results of the liquid dosage form C at 37°C in the 12th week showed an average SC stability of 66.4%, whereas the results of the liquid dosage form D at 37°C in the 12th week showed an SC stability of 71.9%.

[0455]

Discussion

[0456] Based on the analysis of the above results, it was confirmed that compared with liquid dosage form C, liquid dosage form D, which was a composition of liquid dosage form C improved by RSM, increased SC stability by 5.9% at room temperature (20-25°C) and increased SC stability by 5.5% at 37°C as an accelerated condition.

[0457] Furthermore, it was confirmed that in the case of liquid dosage form C, the target of the relevant test of maintaining SC% of 85% or more when stored at a temperature of 25°C for 3 months was also met (89.4% SC), and liquid dosage form D showed an even greater SC stability of 92.8%, thereby obtaining an improved final composition (average percentage after storage for 3 months).

[0458] Therefore, the liquid formulation D composition was successfully developed as the optimal composition capable of maintaining the stability of pDNA better than the liquid formulation C.

[0459] [Conclusion of Example 3]

[0460] This Example 3 confirmed that Liquid Formulation D, which is the final composition derived from the stability of pDNA, is a composition that can maintain pDNA more stably under accelerated conditions of 25°C and harsh conditions of 37°C, compared to Liquid Formulation C confirmed in previous studies.

[0461] In fact, the composition of liquid dosage form C showed 89.4%, which exceeded 85% (%SC) at 25°C and 3 months, which is the VM202 DP spec standard. On the contrary, liquid dosage form D, which is an improved composition, showed 92.8% at 25°C and 3 months, thereby developing a dosage form that can more stably maintain the stability of pDNA in a liquid state.

[0462] It has been confirmed that the liquid dosage form C, which is the composition before improvement, can be applied to VM202DS produced in various production sites, and also meets the SC% stability targeted by the relevant tests, and can be used in the actual production process. Therefore, the liquid dosage form D, which was additionally developed by improving the composition, also showed the same effect, and higher stability was confirmed in terms of stability.

[0463] This was confirmed to be the optimal combination for improving the stability of pDNA through synergy between the components of the liquid dosage form, and it is estimated that it can be stably maintained for a maximum of more than two years under refrigerated conditions, which is the DP storage temperature.

[0464] [Example 4: Long-term stability test of prefilled syringe dosage form]

[0465] The present inventors used the liquid dosage form C and the liquid dosage form D developed through Examples 1 to 3 to conduct a test on long-term stability when prepared as a dosage form for a prefilled syringe.

[0466] Liquid dosage form C and liquid dosage form D containing 0.5 mg / ml plasmid DNA were prepared in the form of vials and prefilled syringes, respectively. The SC% was measured at a temperature of 2-8°C by sampling every 4 weeks for 3 months. The results are shown in Tables 39 and Figure 6 shown.

[0467]

Table 39

[0468]

[0469] As shown in Table 39 and Figure 6 As shown, both the vial and the prefilled syringe maintained SC% of about 95% or more when stored at 2-8°C for more than 6 months (24 weeks), indicating that there was no difference in storage stability even when prepared in the form of a prefilled syringe.

[0470] [Example 5: Stability test in formulations C and D using various plasmids]

[0471] For liquid dosage forms C and D developed in Examples 2 and 3, experiments were conducted to confirm whether the same stability was shown in the case of plasmids other than VM202. pCK-SDF-1a (WO2016 / 048105A1), pTx-IGF-1X10 (WO2020 / 016655A2) and pCMV3-cMet-flag (Sino Biologics, China) were used as plasmids. The experiment was performed in the same manner as in the existing embodiments. For liquid dosage forms C and D of the three plasmids, SC% was measured by storing them at 2-8°C and 25°C for 4 weeks, respectively.

[0472] The results are shown in Table 40 below.

[0473]

Table 40

[0474]

[0475] As shown in Table 40, it was confirmed that the three plasmids showed high stability in the liquid formulation C or liquid formulation D. In particular, pCK-SDF-1a showed considerable decrease in stability (SC% dropped sharply to 80%) when briefly exposed to 0.9% sodium chloride in the initial composition, but the SC% did not decrease significantly after 4 weeks in formulation C or formulation D and remained stable. This proved that liquid formulation C or liquid formulation D, especially liquid formulation D, is a formulation that can stably maintain very unstable plasmid DNA.

[0476] [Example 6: Long-term stability of prefilled syringe dosage forms using multiple plasmids]

[0477] The three plasmids pCK-SDF-1a (WO2016 / 048105A1), pTx-IGF-1X10 (WO2020 / 016655A2) and pCMV3-cMet-flag (Sino Biologics, China) used in Example 5 were prepared into a prefilled syringe dosage form using liquid dosage form D, and the stability after storage for 4 weeks was confirmed by measuring SC%.

[0478] The results are shown in Table 41.

[0479]

Table 41

[0480]

[0481]

[0482] As shown in Table 41, similar to the results of Example 5, it was confirmed that when Formulation D was stored in the form of a prefilled syringe for 4 weeks, the three plasmids were very stable.

Claims

1. A liquid dosage form of plasmid DNA, characterized in that: Contains 30-50 mM potassium phosphate, 0.5-1.5% sodium chloride and plasmid DNA. pH is 7.5-8.

5.

2. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The liquid dosage form contains 40 mM potassium phosphate.

3. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The above liquid dosage form contains 0.9% sodium chloride.

4. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The pH of the above liquid dosage form is 8.

0.

5. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The plasmid DNA in the liquid dosage form can still maintain 80-100 SC% after being stored at 20-30°C for 6 months.

6. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The liquid dosage form further comprises sucrose, trehalose, mannitol, sorbitol, leucine or a combination thereof.

7. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The liquid dosage form further comprises 1-2% sucrose, 0.5-2% trehalose, 0.01-1% sorbitol, 0.05-0.5% leucine or a combination thereof.

8. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: Contains the above plasmid DNA at a concentration of 0.01-5 mg / ml.

9. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The above liquid dosage form also contains 0.15% to 1.5% mannitol.

10. The liquid dosage form of plasmid DNA according to claim 9, characterized in that: The plasmid DNA in the above liquid dosage form still maintains 90-100 SC% after being stored at 2-8°C for at least 6 months.

11. The liquid dosage form of plasmid DNA according to claim 9, characterized in that: The plasmid DNA in the above liquid dosage form still maintains 60-100 SC% after being stored at a temperature of 15-30°C for at least 3 months, 4 months, 5 months or 6 months.

12. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The liquid dosage form further comprises 0.001% to 0.3% mannitol, 0.05% to 0.5% sorbitol, 0.05% to 0.5% sucrose, 0.15% to 3% trehalose, 0.01% to 1% leucine, or a combination thereof.

13. The liquid dosage form of plasmid DNA according to claim 12, characterized in that: The plasmid DNA in the above liquid dosage form still maintains 90-100 SC% after being stored at a temperature of 2-8°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months.

14. The liquid dosage form of plasmid DNA according to claim 12, characterized in that: The plasmid DNA in the above liquid dosage form still maintains 80-100 SC% after being stored at a temperature of 20-30°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months.

15. The liquid dosage form of plasmid DNA according to claim 1, characterized in that: The liquid dosage form further comprises 0.001% to 0.3% mannitol, 0.05% to 0.5% sorbitol, 0.05% to 0.5% sucrose, 0.15% to 3% trehalose, 0.045-0.055% leucine or a combination thereof.

16. The liquid dosage form of plasmid DNA according to claim 15, characterized in that: The above liquid dosage form contains 37-37.3 mM potassium phosphate.

17. The liquid dosage form of plasmid DNA according to claim 15, characterized in that: The above liquid dosage form contains 0.975-1.0% sodium chloride.

18. The liquid dosage form of plasmid DNA according to claim 15, characterized in that: The plasmid DNA in the above liquid dosage form still maintains 90-100 SC% after being stored at a temperature of 2-8°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months.

19. The liquid dosage form of plasmid DNA according to claim 15, characterized in that: The plasmid DNA in the above liquid dosage form still maintains 80-100 SC% after being stored at a temperature of 20-30°C for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months or 9 months.

20. The liquid dosage form of plasmid DNA according to any one of claims 1 to 19, characterized in that: The above liquid dosage forms are prepared as vials, ampoules, bottles or prefilled syringes.